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The DNA damage response (DDR) represents the primary line of defense 
against exogenous and endogenous genotoxic agents that threaten the stability of our 
genomes.  The ATM and ATR pathways are central to the response to DNA-damage 
and their understanding can bring important information in the fight against inborn 
disease and cancer. 
While the roles for the ATM pathway in DDR are well understood, the lack of 
a model organism for the ATR pathway has impeded its understanding.  Here I show 
how we use Hus1, a component of the RAD9-RAD1-HUS1 heterotrimeric clamp and 
a vital member of the ATR pathway, to deregulate the ATR pathway and dissect its 
importance in development and disease.  This was done by engineering in mice a 
Hus1 allelic series by combining the wild-type (Hus1+) with a hypomorphic (Hus1neo) or 
null (Hus1Δ1) alleles.  As opposed to the germline constitutive deletion that leads to 
embryonic lethality, Hus1 hypomorphic mice are born at expected frequencies and 
show no overt phenotype but have increased levels of genomic instability. Thus they 
have enough Hus1 to deal with physiologic stress and could be used for our research. 
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To investigate the in vivo physiologic relationship between the ATM and ATR 
pathways I crossed the Hus1 allelic series on an Atm null background and showed that 
the interaction between the two pathways is critical for normal development.  When 
the two pathways are deregulated simultaneously a synthetic lethal interaction is 
created.  While part of the Hus1/Atm double mutant mice die during development 
due an apparent incapability to deal with replication stress, the survivors suffer from 
developmental defects including dwarfism and skeletal defects.  To further understand 
the interplay between these two pathways in response to genotoxins Hus1 single 
mutant and Hus1/Atm double mutant mice were subjected to specific genotoxin 
treatments.  This analysis showed that in adult tissues there is a clear separation of 
function between the ATM and ATR pathways, with ATM being the main responder 
to DNA breaks while the ATR pathway responds mainly to replication stress such as 
that caused by mitomycin C.  In summary this thesis brings important new 
information about the relationship between the two main DDR response pathways 
leaded by ATM and ATR and substantiates their joint role in development and 
disease.  Moreover we now have a better understanding of how these interactions can 
be used for creating better therapies.  
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 CHAPTER 1 
 
LITERATURE REVIEW 
 
1.1 DNA damage response  
Our genomes are exposed daily to tens of thousands of DNA lesions that can 
impair normal cellular processes and can eventually lead to disease and death.  DNA-
damaging agents are both exogenous and endogenous in nature and can cause a 
variety of DNA lesions, from single base deletions to single and double stranded 
DNA breaks (SSBs; DSBs) (Jackson and Bartek 2009).  No matter the origin and type 
of lesions, in order to maintain homeostasis, replication fidelity, and impede cancer 
formation, eukaryotic cells have to neutralize these existential threats; the necessary 
response to damage is repair.  However, if the injuries overwhelm the repair 
mechanisms viable alternatives are senescence or programmed cell death (Branzei and 
Foiani 2008).  The DNA damage response (DDR) encompasses a signal transduction 
network that senses these lesions and triggers a series of posttranslational and 
transcriptional modifications that direct cell fate (Shiloh 2003).   
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Figure 1.1 Simplified view of the roles DNA-PK, ATM and ATR in DDR.  The 
ATM and DNA-PK pathways respond primarily to dsDNA lesions. The ATR 
pathway responds to ssDNA lesions, and requires the RAD9-RAD1-HUS1 (9-1-1) 
complex for efficient phosphorylation of downstream effector CHK1.  There is 
significant crosstalk between these pathways, and together they signal for cell cycle 
arrest, DNA repair, apoptosis, and fork stabilization in response to DNA damage.  
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Table 1.1 Common DNA-damaging therapeutic agents and their consequences 
Cancer treatment Damaging agent Lesion Repair pathawy 
Radiotherapy and 
radiomimetics 
IR; Oxygen 
radicals; 
Bleomycin 
SSBs; DSBs; 
base damage  
Base excision repair (BER)(Fortini 
and Dogliotti 2007) 
Homologous recombination – HR 
Non-homologous end joining - 
NHEJ(O'Driscoll and Jeggo 2006) 
Monofunctional 
alkylators 
Alkylsulphonates; 
Nitrosourea 
compounds; 
Temozolomide 
Base damage 
Bulky adducts 
Replication 
lesions 
BER; 
Nucleotide-excision repair 
(NER)(Hoeijmakers 2001);   
Translesion synthesis (TLS)(Loeb and 
Monnat 2008; Raschle, Knipscheer et 
al. 2008); 
Fanconi anaemia repair pathway (FA);  
Mismatch repair (MMR)(Li 2008);  
RecQ-mediated repair (Rec-Q) 
Bifunctional 
alkylators 
Nitrogen mustard 
Mitomycin C 
Cisplatin 
Double-strand 
breaks;  
DNA 
crosslinks; 
Bulky adducts 
HR; FA; NER; Rec-Q; TLS 
Antimetabolites 
5-Fluorouracil 
(5FU) 
Thiopurines 
Folate analogues 
Replication 
lesions; Base 
damage 
BER 
Topoisomerase 
inhibitors 
Camptothecins 
Etoposide (VP16) 
SSBs; DSBs; 
Replication 
lesions 
Rec-Q; HR; FA; NHEJ 
Replication 
inhibitors 
Aphidicolin 
Hydroxyurea 
Replication 
lesions; DSBs HR; FA; NHEJ 
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Indispensable to DDR are the cell cycle checkpoints that recognize the damage 
and coordinate the ensuing response with the progression of the cell cycle.  The cell 
cycle checkpoints are conserved from yeast to humans and have as central players the 
ATM and ATR phosphatidylinositol-3 kinase related kinase (PIKK) family (Abraham 
2001).  Cells that experience DNA damage during the first phase of the cell cycle (G1) 
activate the G1-checkpoint primarily via an ATM dependent mechanism (Abraham 
2001; Branzei and Foiani 2008).  Once activated, ATM phosphorylates p53 directly or 
indirectly (via CHK2) to upregulate the expression of the p21 cyclin-dependent kinase 
inhibitor and induces cell cycle arrest and promote repair.  
The ATR pathway plays redundant roles in imposing this checkpoint since 
activation of p53 is reinforced and maintained by ATR.  Once cells enter S-phase they 
rely mainly on the ATR pathway for imposing the intra-S checkpoint.  During this 
phase replication stress can induce an array of DNA modifications that are kept on 
check by the ATR pathway.  Complete and accurate DNA replication is critical to 
prevent mitotic catastrophe that can results from incomplete or inaccurate DNA 
replication.  Impairment of the ATR pathway is incompatible with viability.  When 
activated, the checkpoint leads to the proteosome-mediated degradation of CDC25A 
thus the failure to maintain activation of cyclin·cdk2 complexes stimulating inhibition 
of DNA synthesis and DNA repair through high-fidelity homologous recombination.  
When the pathway fails and DSBs are formed the ATM kinase participates to 
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reinforcing the checkpoint by phosphorylating CHK2 kinase (Abraham 2001; Branzei 
and Foiani 2008; Branzei and Foiani 2010). 
On the other hand at the final stage of the cell cycle the G2-checkpoint relies in 
similar manner on ATM and ATR.  When damage is produced just before the 
completion of S-phase, the G2-checkpoint is triggered primarily by ATR.  When 
damage affects directly the G2-phase, the checkpoint relies mainly on ATM.  No 
matter when or how it is activated the G2-checkpoint is imposed via the CDC25C 
phosphatase, which prevents the activation of the mitotic progression (Abraham 
2001). Furthermore, another member of the PIKK protein family, DNA-PK, is also 
involved in DSBs damage recognition and repair through non-homologous end 
joining (NHEJ), but its involvement in checkpoint signaling remains elusive (Collis, 
DeWeese et al. 2005) (Figure 1.1).  The deregulation of these pathways results in 
increased genomic instability (GIN) that can lead to severe human disorders including 
cancer.  Thus, a better understanding of their joint role in DDR and their link to other 
homeostatic and developmental pathways represents an important step in creating 
molecular maps critical for establishing new therapeutic strategies.  
1.2 The ATM pathway. 
Following ionizing radiation (IR), ATM initiates a DDR pathway that senses 
DSBs formation and signals to downstream effectors to activate cell cycle 
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checkpoints.  The role of ATM is not restricted to signaling toxic DSBs lesions, as it 
also plays important roles in the repair of physiological DSBs during V(D)J 
recombination (Lavin 2008) and oxidative stress response (Skinner 2010). 
In unperturbed cells, ATM exists as a dormant dimer or high-order multimer 
that together with the MRE11-RAD50-NBS1 (MRN) complex monitors DNA 
integrity.  Once DSBs are formed, the MRN complex tethers the DNA loose ends 
and concomitantly catalyses the activation of ATM, which undergoes rapid auto-
phosphorylation at Ser1981 in humans (1987 in mouse) and phosphorylates the 
histone H2A variant H2AX (Bakkenist and Kastan 2003; Stracker and Petrini 2011).  
Phospho-H2AX (γ-H2AX) generates a chromatin microenvironment that allows and 
promotes the recruitment of other signaling molecules such as MDC1, 53BP1, and 
BRCA1, creating DNA-damage foci that act as a platform for the accumulation of 
damage-response and repair factors (Bonner, Redon et al. 2008).  Subsequently, ATM 
signals to the checkpoint machinery by phosphorylating checkpoint kinase 2 (CHK2) 
and the transcription factor and tumor suppressor p53.  Once activated p53 regulates 
the expression of proteins involved in regulating cell cycle progression such as the 
cyclin dependent kinase inhibitor p21 that arrests the cell cycle progression 
(Abraham, Zhou et al. 2001).  However, if the repair machinery cannot resolve the 
damage in a timely manner the ATM pathway will cause permanent arrest 
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(senescence) or will induce cell death by activating the apoptotic pathway via p53-
dependent or independent mechanisms (Cotter 2009). 
In addition to signaling to the cell cycle checkpoint machinery, ATM is 
involved in DNA repair, accounting for 15-25% of the DSBs repair (Goodarzi, 
Noon et al. 2008).  The ATM-dependent repair dynamics depend both on the phase 
of the cell cycle and the chromatin condensation status.  Even if in the last decade 
the understanding of the ATM pathway has benefited from a plethora of new 
findings, there are still many unknowns about ATM activation and its role in 
signaling and repair (Lavin 2008). 
1.3 ATM pathway and human pathology 
In humans, mutations in the Atm gene lead to Ataxia-telangiectasia (A-T, 
OMIM #208900), an autosomal recessive syndrome characterized by early onset of 
cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, sterility, 
chromosomal instability, increased sensitivity to IR and high risk of developing 
lymphoid tumors (Lavin and Shiloh 1997). Heterozygous carriers of AT mutations 
have been strongly linked to breast and other cancers (Angele, Romestaing et al. 
2003; Thorstenson, Roxas et al. 2003; Renwick, Thompson et al. 2006).  The cause of 
death in A-T patients is respiratory system disease or cancer (McKinnon and 
Caldecott 2007; McKinnon 2012).  
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1.3.1 ATM pathway mouse models  
To better understand the role of ATM in pathology, several laboratories have 
created mouse models for ATM pathway impairment.  Atm knockout mice (Barlow, 
Hirotsune et al. 1996; Elson, Wang et al. 1996; Xu and Baltimore 1996) and 
knockout mice of other members of the ATM pathway such as Chk2, p21 or p53 
(Donehower, Harvey et al. 1992; Deng, Zhang et al. 1995; Takai, Naka et al. 2002) 
are viable.  Atm-/- mice have a reduced body weight, increased GIN, hypersensitivity 
to IR and die between 3 to 6 months of age because of thymic lymphomas.  In 
contrast to A-T patients, Atm-/- mice present mild, if any, neurological abnormalities; 
Atm+/- mice have an increased sensitivity to IR but no cancer predisposition (Barlow, 
Hirotsune et al. 1996; Elson, Wang et al. 1996; Xu, Ashley et al. 1996).  In mice and 
humans failure to repair DSBs can lead to chromosomal rearrangements or 
translocations and thus represent a high risk of oncogene activation thus most of the 
phenotypes associated with A-T are due, directly or indirectly, to the incapability to 
respond to DSBs (Lavin 2008). 
1.4 The ATR pathway 
The ATR pathway responds to a variety of stresses including exogenous 
agents such as UV-light and endogenous replication stress (Cimprich and Cortez 
2008).  Once the replication machinery encounters such lesions, the polymerase stalls 
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and uncouples from the replicative helicase that keeps unwinding the DNA, leaving 
behind large stretches of single stranded DNA (ssDNA) that are immediately 
recognized and coated by the ssDNA-binding trimeric protein replication protein A 
(RPA). The ssDNA/RPA complex formation is the signaling event prerequisite for 
damage recognition and ATR activation. 
ATR damage recognition depends on its permanent partner the ATR 
interacting protein (ATRIP) that recognizes and binds RPA (Zou and Elledge 2003) 
and its colocalization with the RAD9-RAD1-HUS1 (9-1-1) complex. The 9-1-1 
complex, a proliferating cell nuclear antigen (PCNA) like clamp, is independently 
loaded onto the 5`DNA end adjacent to a stretch of ssDNA/RPA by the RAD17-
RFC clamp loader in an ATP dependent manner (Menoyo, Alazzouzi et al. 2001) and 
brings together through its RAD9 tail the DNA topoisomerase II-binding protein-1 
(TopBP1) (Delacroix, Wagner et al. 2007) and the RAD9-RAD1-HUS1 interacting 
nuclear orphan (RHINO)(Cotta-Ramusino, McDonald et al. 2011) that facilitate 
ATR activation (Figure 1.2). 
Once activated, ATR phosphorylates checkpoint kinase 1 (CHK1) that 
stabilize the fork, inhibits new origin firing and initiates the cell cycle checkpoint 
allowing for damage repair (Cimprich and Cortez 2008).  ATR is critical for cell 
survival (Brown and Baltimore 2000) and functions as master regulator of the intra-S   
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Figure 1.2. Simplified model of ATR activation at stalled replication forks.  
ATR activation begins when RPA binds to and stabilizes ssDNA.  RPA coated single 
stranded DNA recruits the ATR-ATRIP complex to the site of damage.  
Independently, the RAD9-HUS1-RAD1 heterotrimeric clamp complex is loaded at 
recessed 5` DNA ends; RHINO acts to recruit and facilitate TopBP1 to the phospho-
tail of RAD9 thus activating ATR. Once activated ATR phosphorylates CHK1 and 
other targets to prevent cell cycle progression and stop new origin firing, promote 
fork stability to allow for DNA repair and when damage is repaired promote fork 
restart.  
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cell cycle checkpoint, although its role during G1/S and G2/M checkpoints must not 
be disregarded (Branzei and Foiani 2008).  Together, these data demonstrate that 
failure to initiate the ATR pathway results in damage accumulation and successive 
increase in genomic instability causing devastating cellular phenotypes (Brown and 
Baltimore 2000). 
1.4.1 HUS1 is an essential component of the ATR pathway 
Indispensable for the ATR pathway is the RAD9-RAD1- HUS1 complex (9-1-
1).  The complex was discovered screen for genes important for the response to 
hydroxyurea (HU) induced DNA damage and that would induce cell cycle arrest in 
yeast (Enoch, Carr et al. 1992).  The 9-1-1 components are conserved from yeast to 
humans and form a clamp-like complex critical for the response to DNA damage 
(Volkmer and Karnitz 1999).  Later it was demonstrated that 9-1-1 is the structural 
ortholog PCNA, a homotrimeric sliding clamp that tethers DNA polymerase 
(Griffith, Lindsey-Boltz et al. 2002). Analogous to PCNA that requires the replication 
factor C (RFC) for its loading, the 9-1-1 is loaded by RAD17-RFC complex.  These 
observations proposed similar roles and structures for these complexes (Venclovas 
and Thelen 2000). 
Recent crystallography data confirmed the structural hypothesis (Dore, 
Kilkenny et al. 2009; Sohn and Cho 2009; Xu, Bai et al. 2009) but proposed that 
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while PCNA and 9-1-1 share similarities they also perform distinct functions.  
Though both PCNA and 9-1-1 are loaded onto ssDNA, PCNA is loaded during 
replication at the primer-template junctions (recessed 3’ end) and slides over the 
double stranded DNA (dsDNA).  On the other hand 9-1-1 is loaded onto dsDNA at 
recessed 5’ ends at sites of DNA damage and is expected to slide along the 
phosphate backbone of the DNA.  Crystal structure data suggests though that the 9-
1-1 complex directly interacts with DNA rather than slides off linear DNA (Sohn 
and Cho 2009).  Thus PCNA acts as a processivity factor and moves along with the 
replication machinery tethering pol δ and ε, while 9-1-1 is docks at sites of DNA 
damage or where forks stall and acts as a landing platform for additional checkpoint 
and repair proteins (Shiotani and Zou 2009). 
Although initial research showed that 9-1-1 and PCNA can be ubiquitinated 
(Majka and Burgers 2004; Fu, Zhu et al. 2008; Tsutakawa, Van Wynsberghe et al. 
2011) to recruit DNA-repair factors like translesion synthesis polymerase or that they 
can stimulate BER (Jansen, Fousteri et al. 2007), recent evidence disputes this idea 
for 9-1-1 (Davies, Neiss et al. 2010; Inagaki, Sleddens-Linkels et al. 2011). 
All the 9-1-1 subunits, including HUS1, are vital for structural integrity of the 
complex and are considered critical members of the ATR pathway (Weiss, Enoch et 
al. 2000; Hopkins, Auerbach et al. 2004; Han, Hu et al. 2010).  In mouse, the Hus1 
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gene consists of nine exons that once transcribed give rise to a 4.2 kb cDNA 
transcript that is translated into to a 32-kDa HUS1 protein.  HUS1 is expressed in 
most adult tissues and within the complex functions to promote genotoxin induced 
ATR activation (Weiss, Kostrub et al. 1999).  Constitutive Hus1 knock-out in mice 
results in mid-gestational embryonic lethality caused by widespread apoptosis (Weiss, 
Enoch et al. 2000).  Hus1 null cells accumulate genome damage, show increased 
apoptosis, and fail to proliferate, however p53 or p21 deletion permits them to grow 
(Weiss, Enoch et al. 2000; Zhu and Weiss 2007). Hus1 is essential for fragile site 
stability, since in Hus1 null cells spontaneous chromosomal abnormalities take place 
preferentially at common fragile sites via a p53 independent mechanism (Zhu and 
Weiss 2007). Upon genotoxic stress Hus1-/-p21-/- cells are incapable to activate the 
ATR pathway (Weiss, Matsuoka et al. 2002) and display a severe intra-S checkpoint 
defect (Weiss, Leder et al. 2003).  Since loss of HUS1 leads to increased GIN and is 
not compatible with life, the roles for the 9-1-1 complex in-vivo in both physiologic 
and pathologic circumstances are not fully understood. 
9-1-1 has also been shown to be an integral component of the telomeres.  
RAD9 preserves telomere integrity and prevents chromosomal fusions in mouse and 
human cells (Verdun and Karlseder 2006). In both humans and mice Hus1-deficient 
MEFs and thymocytes show severe telomeric shortening.  Moreover, in cell lysates, 
the 9-1-1 complex was demonstrated to interact with catalytically competent 
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telomerase and act as a positive regulator of its DNA polymerase activity providing a 
mechanistic link between the activity of DNA-damage-checkpoint proteins and the 
telomere-maintenance machinery (Francia, Weiss et al. 2006; Francia, Weiss et al. 
2007)  
1.4.2 HUS1 can act independently of ATR to promote repair 
Cell culture systems have shown that 9-1-1 is directly involved in BER.  The 9-
1-1 complex interacts and stimulates the activity of the important BER members 
apurinic/apyrimidinic endonuclease 1 (APE 1) and DNA ligase I (Helt, Wang et al. 
2005; Wang, Lindsey-Boltz et al. 2006) and that acts as a damage-specific activator of 
flap endonuclease 1 (FEN1) that cleaves the flap remaining following DNA repair 
(Friedrich-Heineken, Toueille et al. 2005 1115).  Moreover, it was proposed that 9-1-
1 also acts in BER by attracting POL-β to DNA damage sites, linking the checkpoint 
response and DNA repair (Toueille, El-Andaloussi et al. 2004).  By interacting with 
the MYH (MutY glycosylase homologue), 9-1-1 can increase replication fidelity by 
removing adenines or 2-hydroxyadenine misincorporated opposite 8-oxo-G (7,8-
dihydro-8-oxo-guanine)(Shi, Chang et al. 2006).  This indicates that the complex is 
directly involved in long patch BER (LP-BER) and together with its independent role 
in ATR activation realizes a link between DNA damage checkpoint and repair 
through BER. 
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Since PCNA interacts with polymerase δ and ε as well as with some 
translesion synthesis polymerases the 9-1-1 complex has been examined for similar 
interactions (Jansen, Fousteri et al. 2007; Navadgi-Patil and Burgers 2009).  To this 
extent HUS1, has been shown to physically interact with POL-K, a translesion 
synthesis factor (Kai and Wang 2003), and influence POL-ζ mutagenesis processes 
(Sabbioneda, Minesinger et al. 2005). Additionally, the 9-1-1 complex has been 
shown to act as a member of mismatch repair pathway following treatment with the 
DNA methylating agent N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) when it 
physically interacts with MSH2, MSH3, and MSH6 mismatch recognition factors 
(Bai, Madabushi et al. 2010).  Undoubtedly, the 9-1-1 complex is involved in a broad 
range of repair processes coordinating checkpoint signaling and repair through 
mechanisms the extent of which are not yet completely understood. 
1.4.3 ATR pathway and human pathology 
In humans, impairment of the ATR pathway leads to Seckel syndrome (ATR-
SS) (OMIM #210600) an autosomal recessive disorder characterized by 
proportionate dwarfism, severe microcephaly, craniofacial abnormalities and mental 
retardation (Alderton, Joenje et al. 2004; O'Driscoll, Dobyns et al. 2007).  Moreover 
subsets of these patients termed Atr-SS have an ATR splicing mutation that leads to 
hypomorphic ATR expression (O'Driscoll and Jeggo 2003). 
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Apart developmental defects, since GIN is a classic hallmark of cancer and 
defects in ATR result in chromosomal aberrations it is not unexpected that 
mutations of members of the ATR pathway have also been implicated in cancer 
development.  Increased mutation frequencies in ATR and CHK1, have been found 
to correlate significantly with advanced tumor grade (Vassileva, Millar et al. 2002).  
Truncating mutations in ATR exon 10 of have been described in cancers exhibiting 
microsatellite instability (Menoyo, Alazzouzi et al. 2001; Lewis, Mullany et al. 2005).  
Additionally, truncating ATR mutations present in endometrial cancers are associated 
with aggressiveness as evidenced by reduced disease-free survival (Zighelboim, 
Schmidt et al. 2009).  In colon cancers ATR status was not associated with tumor 
stage; however ATR mutations were associated with a trend toward improved 
disease-free survival suggesting that ATR mutations may affect clinical behavior and 
response to therapy in colon cancers (Lewis, Bakkum-Gamez et al. 2007).  These 
differences in prognosis may be due to tissue-specific variances in ATR requirement, 
since lower levels of RAD9 in some prostate cancers acts to prevent tumor 
development (Wang, Hsu et al. 2004).  The role of ATR pathway in tumor biology 
remains to be established as, to date, complete loss of any component of the ATR 
pathway has not been found in any human tumor, endorsing the ATR role as tumor 
suppressor. 
 
 
   
19 
1.4.4 ATR pathway mouse models 
Unlike the ATM pathway the members of the ATR pathway are vital for 
survival.  ATR (Brown and Baltimore 2000; de Klein, Muijtjens et al. 2000) , RAD17 
(Budzowska, Jaspers et al. 2004), RAD9 (Hopkins, Auerbach et al. 2004), RAD1 
(Han, Hu et al. 2010), HUS1(Weiss, Enoch et al. 2000), or CHK1 (Liu, Guntuku et 
al. 2000; Takai, Tominaga et al. 2000) constitutive knockout mice all die during early 
embryogenesis.   
In order to understand the requirement for ATR in adults and circumvent this 
lethality, conditional mouse models have been created.  Tamoxifen inducible ATR 
knockout in adult mice caused a dramatic loss of tissue-specific stem and progenitor 
cell populations resulting in an overt progeroid syndrome; ATR has been shown to 
be essential for highly proliferative tissues while no structural or degenerative 
phenotypes were observed in postmitotic organs such as the brain (Ruzankina, 
Pinzon-Guzman et al. 2007).  This Atr mosaic mouse model suggested that most of 
the phenotypic characteristics of the Atr-SS are due Atr insufficiency during 
embryonic development.  Surprisingly, modulating the ATR-SS A2101G 
synonymous mutation in mouse resulted in no phenotype (Ragland, Arlt et al. 2009); 
however, when the entire Atr human sequence incorporating the splicing defect was 
engineered, an Atr hypomorphic, Seckel-like mouse was created (Atrs/s)(Murga, 
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Bunting et al. 2009).  Surviving Atrs/s mice recapitulated the human Atr-SS and 
showed dwarfism, craniofacial abnormalities, brain defects and pancytopenia.  Unlike 
human patients Atrs/s mice presented severe ageing phenotypes that caused them to 
die by six months of age.  Atrs/s embryos showed increased level of γ-H2AX and 
apoptosis accumulation while the presence of GIN was not tested in the adults.  The 
authors proposed that all the adult phenotypes were the result of intrauterine 
programming (O'Driscoll 2009; Fernandez-Capetillo 2010). 
The caustic phenotypes associated with constitutive ATR pathway 
deregulation impeded the functional analysis of its role in genotoxic sensitivity and 
tumor development.  Heterozygous mice were used for genetic analysis.  By crossing 
the Atr+/- mice on a mismatch repair deficient background it was observed that Atr+/-
/Mlh1-/- double mutant mice show a haploinsufficient tumor suppressor function and 
are highly prone to embryonic lethality.  These data suggests that MMR proteins 
functionally interact with ATR during the cellular response to genotoxic stress (Fang, 
Tsao et al. 2004; Lee, Jin et al. 2012).  Application of the 7,12-
dimethylbenzanthracene (DMBA) carcinogen onto the skin of animals with 
conditional Rad9 deletion in the skin caused earlier onset of tumors and senile skin 
plaques, showing that RAD9 is critical for the prevention of skin tumors in mice 
(Hu, Liu et al. 2008).  Chk1+/- mice show increased number of S phase arrested cells 
due to increased spontaneous DNA damage resulting in phenotypes that contribute 
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to tumorigenesis (Lam, Liu et al. 2004).  Additionally, Chk1 heterozygosity modestly 
accelerates the tumorigenesis seen in Wnt1 transgenic mice, supporting the 
haploinsufficient tumor suppressor role of CHK1 (Liu, Guntuku et al. 2000).  Taken 
together, these reports suggest that in mice components of the ATR pathway act as 
important players in tumor biology.   
Our laboratory created a conditional Hus1 allele (Hus1flox) where exons two and 
three are flanked by loxP sites. When Cre was express in various tissues the 
conditional knockout mice were produced at unexpectedly low frequency and 
showed limited inactivation of the conditional allele, suggesting that Hus1-deficient 
cells were at a strong selective disadvantage in adult animals.  This was not the case in 
the lung and mammary gland, highlighting varying requirements for Hus1 in different 
tissues (Levitt, Liu et al. 2005). We ultimately made an allelic series featuring 
incrementally reduced Hus1 function by using the hypomorphic allele Hus1neo in 
combination with null (Hus1∆1) or wild-type (Hus1+) alleles (Figure 1.3).  Hus1neo/∆1 
mice had the lowest Hus1 expression in the series and showed increased genomic 
instability and genotoxin hypersensitivity. These mice have enough Hus1 to maintain 
cellular homeostasis, but not enough to respond to stress. Thus, a viable mouse 
model defective for the ATR pathway was created (Levitt, Zhu et al. 2007).  
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Figure 1.3. Alleles used to construct the Hus1 allelic series, which expresses 
decremental Hus1 levels.  (A) Schematic representation of the Hus1 alleles 
generated in systems for constitutive and conditional Hus1 inactivation. (B) Northern 
blot analysis of duplicate samples of primary MEF cultures of the indicated genotypes 
hybridized with a 32P-labeled Hus1 or Gapdh cDNA probe. 
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1.5 The DNA-PK pathway 
DSBs are the most harmful lesions that genomes can experience. 
Consequently cells have evolved multiple repair enzymes that in association with the 
cell cycle checkpoints promote repair and allow survival. Central to DSBs repair are 
two essentially distinct pathways: HR and NHEJ.  Although the exact mechanisms 
that dictate the use of one over the other are not completely known the cell cycle 
stage has unambiguous influence on this choice (Hoeijmakers 2001; Branzei and 
Foiani 2008).   
Under control of the RAD52 epistasis group, HR is an error-free repair 
mechanism that acts during the S and G2 phases of the cell cycle and allows for 
precise repair of the damage using the sister chromatid as a template (Moynahan and 
Jasin 2010).  On the other hand NHEJ is an error-prone repair mechanism that acts 
in the G1/G0 and M phases of the cell cycle and during the development of B- and 
T-lymphocytes during V(D)J recombination (Weterings and Chen 2008) and class 
switch recombination (CSR) (Cook, Oganesian et al. 2003).  Although inaccurate, 
NHEJ is involved in the repair of most DSBs that an adult organism experiences and 
is under the control of the DNA-PK, a PIKKs protein kinase containing a regulatory 
(KU70/80) and a catalytic subunit (DNA-PKcs) (Collis, DeWeese et al. 2005).  
NHEJ integrates the recognition, tethering and processing of the broken DNA-ends 
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with ligation. DNA-PK plays an important sheltering role at telomeres(de Lange 
2002) and additionally it has been reported to phosphorylate, in-vitro and in-vivo, 
numerous protein substrates involved both in NHEJ and other cellular 
processes(Meek, Dang et al. 2008). 
Humans deficient for NHEJ factors develop severe combined 
immunodeficiency (SCID) characterized by opportunistic infections, chronic diarrhea 
and failure to thrive.  A subset of these patients are radiosensitive (RS-SCID) and 
have a greater risk of developing lymphomas (McKinnon and Caldecott 2007).  
Remarkable, unlike in humans, the spontaneous genetic forms of SCID in animals 
are DNA-PKcs mutations (mice, dogs and horses).  DNA-PK knock-out mice 
models are viable, fertile, show increased IR sensitivity, a SCID-like phenotype and 
variable risk of developing lymphomas (Smith and Jackson 1999).  One proposed 
theory is that in human DNA-PK plays additional roles that are critical for survival. 
This hypothesis is reinforced by the fact that primate cells express almost 50 folds 
more DNA-PK than rodents whereas all the other NHEJ factors are expressed at 
lower levels (Meek, Dang et al. 2008).  Additionally, due to the identification of 
DNA-PK upregulation in several radio-protected cancers, it has been proposed that 
DNA-PK inhibitors have a great potential in enhancing the sensitivity of cancer cell 
to therapy.  Since then several highly specific DNA-PK inhibitors have been 
developed and are currently tested for their efficacy (Collis, DeWeese et al. 2005).  
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Table 1.2. Mouse models for ATM, ATR and DNA-PK pathways deficiency 
For extensive description consult (Donehower, Harvey et al. 1992; Barlow, Hirotsune 
et al. 1996; Elson, Wang et al. 1996; Xu and Baltimore 1996; Brown and Baltimore 
2000; Weiss, Enoch et al. 2000; Takai, Naka et al. 2002; Gatei, Sloper et al. 2003; 
Levitt, Liu et al. 2005; Levitt, Zhu et al. 2007; Ruzankina, Pinzon-Guzman et al. 2007; 
Stracker, Morales et al. 2007; Stracker, Couto et al. 2008; Murga, Bunting et al. 2009; 
Balmus, Zhu et al. 2012) 
 
Mouse model Phenotype 
Atm-/- Reduced body size; IR sensitivity; increased GIN ; 100% die 
with T-cell lymphoma (3-6 months of age) 
Chk2-/- Viable; fertile; radioresistant; apoptotic defect; increased tumor 
predisposition 
p53-/- Early-onset tumor incidence ; increased GIN; 100% die  
Atr-/- Embryonic lethal (< 7.5dpc) 
Atrs/s Hypomorphic; dwarfism (Igf1 dependent); senescence, 
craniofacial defects, brain defects; increased GIN and 
apoptosis at embryonic level 
Hus1-/- Embryonic lethal (9.5dpc) 
Rad1-/- Embryonic lethal (9.5dpc) 
Rad9-/- Embryonic lethal (9.5dpc) 
Chk1-/- Embryonic lethal(before implantation) 
DNA-PK-/- Immunodeficiency; increased GIN and lymphoma risk; 
Atm-/-Chk2-/- p53-/- like phenotype in thymocites; Atm-/- like tumor free 
survival 
Atm-/-p53-/- Significant increased tumor formation  
Chk2-/-p53-/- p53-/--like phenotype  
Chk1-/-p53-/- Embryonic lethal (before implantation) 
Atrs/sp53-/- Rarely born; severe senescence; 100% die by 2 months of age; 
increased GI in MEFs 
Atm-/-Atrs/s  Embryonic lethal ; no data reported (no description given; no 
MEFs generated) 
Atm-/-Hus1neo/ex Embryonic lethal (10.5dpc) 
Atm-/-Hus1neo/neo Dwarfism (Igf1 independent); more than additive GIN; 
craniofacial abnormalities;100% T-cell lymphoma (Atm-/- like) 
p53-/-Hus1neo/ex p53-/- like phenotype (Weiss Lab - unpublished) 
Atm-/-DNA-PK-/- Embryonic lethal (< 11.5dpc) 
DNA-PK-/-Chk2-/- Significant decreased life span due to infections; no tumors  
DNA-PK-/-p53-/- Significant increased tumor formation (lymphoma) 
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1.6 Phosphatidylinositol-3 kinase related kinases crosstalk 
ATM, ATR and DNA-PK are serine/threonine kinases that upon DNA-injury 
localize to the damaged site and initiate DDR.  ATM and ATR have been historically 
involved in signaling to the cell cycle checkpoint whereas DNA-PK`s contribution 
remains controversial.  Throughout the cell cycle ATM and ATR are influenced by a 
multitude of factors that control their overlapping and redundant involvement in 
initiating the G1, S and G2/M checkpoints. These factors halt cell cycle progression 
and make life and death decisions(Abraham, Zhou et al. 2001; Branzei and Foiani 
2008). 
Current molecular data shows that ATM and ATR have over 700 common 
substrates, targeting more than 900 phosphorylation sites(Matsuoka, Ballif et al. 2007; 
Cimprich and Cortez 2008).  DNA-PK shares many of these substrates in-vitro; 
however, only a few have been proved to be physiological significant (Weterings and 
Chen 2008).  Moreover, DNA-PK it is itself an ATM/ATR substrate.  Until recently 
the ATM and ATR pathways have been thought to function in parallel.  The above 
findings are surprising and have prompted researchers to dissect specific interactions 
between the ATM and ATR pathways.  The first level of crosstalk takes place at the 
DNA-breaks themselves. ssDNA can easily yield a DSB whereas the repair of DSBs 
comprises an intermediary, ATM dependent resection step that creates ssDNA 
overhangs thus activating ATR. In addition ATM can enhance ATR activation by 
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phosphorylating TopBP1(Yoo, Kumagai et al. 2007) whilst ATR has been reported to 
directly phosphorylate ATM and activate CHK2 (Stiff, Walker et al. 2006). 
Once activated ATM and ATR will phosphorylate H2AX to create a chromatin 
microenvironment appropriate for repair.  This target is shared with DNA-PK which 
in their absence mediates a γ-H2AX-salvage pathway (Chanoux, Yin et al. 2009).  
Downstream of ATM and ATR, CHK2, CHK1 and p53 can be activated by both 
kinases (Gatei, Sloper et al. 2003; Antoni, Sodha et al. 2007; Balmus, Zhu et al. 2012).  
While the crosstalk at the level of CHK1 and CHK2 kinases is still attributed to 
interconversion of the DNA lesions and subsequent activation of canonical activators 
(Cimprich and Cortez 2008), the phosphorylation of p53(Meek 2009) by ATM, ATR, 
CHK2 and CHK1 has been confirmed by many studies. 
The functional overlap of the ATM and ATR kinases is critical for redundancy 
in checkpoint signaling.  As previously stated the implication of DNA-PK in 
activating the cell cycle surveillance apparatus is disputed and remains to be proven.  
The possibility of crosstalk between the DNA-PK, ATM and ATR with respect to 
activation of CHK1, CHK2, and p53 has been described in several instances 
(Cimprich and Cortez 2008).  In human cancerous cell lines ATR and DNA-PK have 
been shown to cooperate in CHK1 dependent G2 arrest in response to specific drugs 
(Liu, Matsuda et al. 2008).  Other reports hint to a cell type or cell phase specific 
requirement for these interactions.  B and T cells rely more on ATM and DNA-PK 
and have a reduced requirement for ATR; here ATM deficiency results in a DNA-PK 
 
29 
dependent phosphorylation of KAP1, CHK2 and p53(Wang, Guo et al. 2000; 
Arlander, Greene et al. 2008; Callen, Jankovic et al. 2009).  On the other hand in 
fibroblasts exposed to IR, DNA-PK selectively regulates p53-induced apoptosis but 
not cell cycle arrest (Woo, McLure et al. 1998; Araki, Fukumura et al. 1999; Jimenez, 
Bryntesson et al. 1999).  
This pattern of specific PIKKs functional redundancy turned out to be a 
recurrent theme in the cell cycle checkpoint signaling field and in-vivo models that can 
be used to genetically test these interactions have been developed.  Mice models for 
the ATM pathway are viable, show increased GIN, and are predisposed to tumor 
development.  The DNA-PK mouse models are also viable and recapitulate the 
human SCID syndrome.  In contrast, all members of the ATR pathway are critical for 
survival and in-vivo relevant model have long been absent.  Nevertheless several labs 
have created mouse models hypomorphic for the ATR pathway that surprisingly 
showed no tumor phenotypes.  With these models in hand specific genetic interaction 
can now be tested (Table 1.2).   
The genetic experiments using the ATM pathway members confirmed the 
known molecular data and when ATR pathway members were crossed to an ATM 
deficient background the double knockouts reinforced the proposed redundancy.  
Although Atm-/- and DNA-PK-/- mice are viable the Atm/DNA-PK double mutants 
show synthetic lethality emphasizing their cooperative roles in development 
(Sekiguchi, Ferguson et al. 2001).  This relationship is critical at the kinase level since 
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DNA-PK-/-Chk2-/- mice are viable due to ATM redundancy (Guidos, Williams et al. 
1996).  Atrs/sp53-/- mice show a severe acceleration of the Atrs/s senescence phenotype 
while the Atrs/sAtm-/- mice were reported synthetic lethal (Murga, Bunting et al. 2009).  
The severe phenotypes associated with the Atrs/sp53-/- and Atrs/sAtm-/- mice are an 
impediment in understanding the physiological impact of deregulated ATM/ATR 
pathways and their role in checkpoint signaling and pathology.  
Using the Hus1 allelic series will allow us to better understand these 
interactions. Because we have a stepwise deregulation model we will most likely be 
able to circumvent lethality and comprehend the impact of Atm/Hus1 impairment at 
the organism level. 
1.7 Cancer therapy and the non-oncogene addiction  
Cancer therapy usually involves removal of the cancer cells from the affected 
individual (Chabner and Roberts 2005).  This can be done by surgery or the use of 
chemical therapy (chemotherapy) that selectively marks cancer cells for cell death.  
Chemotherapy in combination with surgery is to date the most common treatment, 
although new strategies are in place to improve patient outcome.  
In general, cancer therapy takes advantage of the increased replication 
potential of many tumors and thus directed towards impeding cell cycle progression.  
Cell division can be targeted by inhibition of the mitotic spindle, inhibition of the 
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growth signals required for cell cycle entry or, most commonly, by exploiting the 
effects of DNA-damaging drugs (Table 1.1).  The DDR-targeted drugs can lead to 
cell death either directly or following replication of damaged DNA, thus affecting 
highly replicating tissues.  Different genotoxic agents have been tested in mouse 
models both for understanding the effect on different cancesr and the toxicity 
associated with such treatments.  Common types of DNA-damage that interfere with 
normal cell cycle progression range from DSBs that are caused by clastogens like 
ionizing radiations or bleomycin (Hsiang, Lihou et al. 1989) to DNA base adducts 
caused by alkylating agents.  The alkylating agents can be monofunctional like 
nitrosourea, cyclophosphamide or temozolomide (modifying single bases) (Stevens, 
Hickman et al. 1987; Komotar, Otten et al. 2008; Minniti, De Sanctis et al. 2008) or 
bifunctional like mitomycin C (an antibiotic extracted from Streptornyces caccpitosus) or 
cisplatin (crosslinking two bases creating either intra- or inter- strand-links) (Lehnert 
1998; Borchiellini, Etienne-Grimaldi et al. 2012; Lord and Ashworth 2012) and pose 
severe treats to normal cell cycle progression.  Other than direct DNA-lesions, cell 
cycle can be affected by inhibition of DNA synthesis using DNA polymerase 
inhibitors (aphidicolin) (Ikegami, Taguchi et al. 1978) or affecting dNTP production 
by inhibiting ribonucleotide reductase – RNR (hydroxyurea) or thymidine synthase 
(Bianchi, Pontis et al. 1986). Moreover, since many cancers are defective for the 
DDR pathways, the specific sensitivity of such cancer cells to DNA-damaging agents 
is enhanced. 
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The classical example for the use of such therapies is exemplified by the 
successful use of the poly(ADP-ribose) polymerase (PARP) inhibitors in certain 
DNA repair-deficient cancers, like breast cancer.  When patients with advanced 
triple-negative breast cancers that have BRCA1/2 mutations were treated with DNA-
damaging chemotherapy in combination with the PARP inhibitor iniparib®, increased 
cancer cell death was promoted and this translated in prolonged patient survival 
compared with chemotherapy treatment alone.  This success was due to the fact that 
while normal cells would effectively repair chemotherapeutic induced DNA damage 
via a PARP dependent mechanism, BRCA1/2-deficient cells would be unable to 
carry out repair, ultimately leading to cell death (Ellisen 2011). 
Similar strategies could be used in the context of ATM/ATR pathways. 
Defects in the ATM pathway result in increased sensitivity to DSB inducing agents 
while deficiency in the ATR pathway leads to sensitivity to replication stress inducing 
agents (Abraham and Halazonetis 2012).  Since these compounds were giving 
promising results in killing cancer cells in cell culture systems, their toxicity was 
assessed in animal models before human use.  Wild type mice treated with a 9-10Gy 
whole body IR suffer from a lethal hematopoietic syndrome and die 12 to 20 days 
later.  At doses higher than 15Gy animal succumb 7 to 12 days later to a 
gastrointestinal syndrome (Sinclair 1973; Takai, Naka et al. 2002; Gudkov and 
Komarova 2003).  Consistent with the idea that the ATM pathway is the main 
 
33 
responder to ionizing radiations, Atm-/- mice are hypersensitive to IR and at doses 
higher than 5Gy IR die within 4 to 8 days from a gastrointestinal syndrome (Barlow, 
Hirotsune et al. 1996; Gurley and Kemp 2007).  The analysis of the IR 
pathophysiology in wild type mice revealed acute alterations in the thymus, spleen, 
bone marrow, spermatogonia, epithelia of the gut, hair follicles and abortion of 
embryos at early stages of gestation, changes that are accompanied by apoptosis.  
Analysis of the sensitivity to IR during development revealed that wild type embryos 
are most sensitive to IR during early development (Michel 1989; Gurley and Kemp 
2007).   
Mice treated with 8 mg/kg body weight MMC, representing the median lethal 
dose (LD50) in 14 days survival studies, suffer from hematopoietic, intestinal and 
renal toxicity (Crooke and Bradner 1976; Hamner, Verani et al. 1983; Legha 1985; 
Linette, McGee et al. 1992; Shirakawa, Morita et al. 1993).  In humans, MMC does 
not cross the blood-brain barrier and is widely distributed throughout the body but is 
metabolised mainly in the liver with about 10% being excreted unchanged in the 
urine (Gangolli and Royal Society of Chemistry (Great Britain) 1999).  Mice defective 
for the FA pathway as well as FA patients cannot deal with the cross-links induced 
by MMC and are hypersensitive to this reagent (Moldovan and D'Andrea 2009).  HU 
has been shown to be highly cytotoxic cells deficient for the ATR pathway while little 
effect was seen in the wild type control cells.  The toxicity associated with in vivo 
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administration of HU by i.p. delivery to wild type pregnant mice has shown that 
administration of a 1g/kg body weight dose at E8.5 results in embryo lethality if 
pregnancy is taken to term. Using 400mg/kg and 800mg/kg body weight doses had 
no effect on embryo survival but determined increased cell death in the central 
nervous system (CNS).  The increased apoptosis in the CNS was detectable as early 
as 3 hours post treatment, and showed the highest levels after 12 hours, followed by 
recovery at 48 hours (Woo, Katayama et al. 2003; Woo, Katayama et al. 2004). 
The problem with the original chemotherapeutic treatments is recurrence of 
tumors.  Thus, a better understanding of tumor biology is needed.  Because cancer is 
usually a highly proliferative process associated with defects in DDR the checkpoint 
functionality of many cancers has been studied and, different from what was 
expected many tumors showed an upregulation DDR components such as p53, 
CHK2 or CHK1 as compared to the normal surrounding tissue (Bartek, Bartkova et 
al. 2007).  Although initially it was thought that the increased functionality of these 
DDR components might be due to the increased levels of replication stress that 
come with increased proliferation (Bartkova, Horejsi et al. 2005) current models 
propose that the increased DDR functions as a survival mechanism adapted by 
cancer cells to survive the associated replication stress, thus promoting tumor 
growth. 
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Overexpression of ATR pathway components RAD9, HUS1 and CHK1, for 
example, is seen in human breast tumors (Cheng, Chow et al. 2005), prostate cancers 
(Zhu, Zhang et al. 2008), ovarian cancers (de la Torre, Gil-Moreno et al. 2008) and 
colorectal cancers (Ashwell and Zabludoff 2008).  While many cancer cells are 
defective for the G1 checkpoint (mainly due to ATM pathway mutations) they have 
intact S/G2 checkpoints as they need them to survive.  To test this hypothesis the 
ATR pathway was inhibited in cancer cells and mouse models for ATR deficiency 
and this resulted to increased cell death (Luo, Rockow-Magnone et al. 2001) or 
failure to initiate spontaneous tumor formation in-vivo (Levitt, Zhu et al. 2007; 
Ruzankina, Pinzon-Guzman et al. 2007; Greenow, Clarke et al. 2009; Murga, Bunting 
et al. 2009; Ruzankina, Schoppy et al. 2009; Yazinski, Westcott et al. 2009; Stephanie 
A. Yazinsky in preparation). 
For example while oncogenic RAS and p53 loss-of-function mutations are 
common in many cancers that present limited sensitivity to conventional 
chemotherapy these genetic alterations create a hypersensitivity to ATR pathway 
inhibition (Toledo, Murga et al. 2011).  Moreover synthetic lethal phenotypes were 
observed at cellular level when ATR suppression was combined with oncogenic 
stress caused by H-RasG12V, K-RasG12D, or c-Myc overexpression (Schoppy, Ragland 
et al. 2012).  Similarly, CHK1 inhibitors were highly effective in killing Myc-driven 
lymphomas and AtrS/S mice were protected from developing Myc-induced 
 
36 
lymphomas or pancreatic tumors (Murga, Campaner et al. 2011; Bartek, Mistrik et al. 
2012). 
The observations that cancer cells rely more heavily than normal cells on a 
functional intra-S and G2 checkpoints is currently refer to as the process of “non-
oncogene addiction”.  While non-oncogene addiction genes, are required for 
preserving cancer progression, they do not undergo oncogenic mutations.  The 
concept of non-oncogene addiction accentuates the key impact of these supporting 
networks to tumorigenesis highlighting points of intervention for cancer therapeutics 
(Luo, Solimini et al. 2009). 
Taken together, these results show that ATR pathway is essential for 
maintaining cancer cell viability and can be exploited to sensitize cancer cells to 
common DNA chemotherapeutic drugs.  CHK1 inhibitors are in advanced clinical 
trials that show very promising results (Bartek, Mistrik et al. 2012; Schoppy, Ragland 
et al. 2012).  The current working model states that ATR pathway inhibition drives 
cancer cells death due to increased replication stress because cancer cells cannot 
recover from these insults.   
1.8 Summary and remaining questions  
Due to the lethality associated with complete ATR pathway deficiency and the 
limited mammalian models available for hypomorphic deregulation of this pathway 
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the in vivo relationship between ATM and ATR pathways remained elusive. Moreover, 
since ATR pathway inhibition shows such promising results for improving cancer 
treatment efficacy (Brooks, Oakes et al. 2012; Tang, Dai et al. 2012), it was imperative 
to learn more about the effect of ATR deficiency in normal tissues.  Here we took 
advantage of the unique Hus1 mouse model to answer these questions. 
In Chapter 2 we focus on understanding the relationship between the interplay 
between the ATM and ATR pathway and human inborn disease.  Seckel Syndrome is 
a debilitating disease that we don’t completely understand, mainly because of a lack of 
suitable animal models.  Moreover the characteristic Seckel phenotypes are present in 
many DDR syndromes, implying that they are consequence of increased GIN during 
development, independent of the DDR component mutated.  Additionally, some A-T 
patients like the A-TFresno variant patients show a more severe disease most likely 
because other polymorphism in DDR pathway genes.  By using the Hus1 allelic series 
as a tool we hope to be able to understand better what is the relationship between the 
two main DDR pathways and development and disease, both at organism and cellular 
levels.  The Hus1 allelic series will be crossed on an Atm-/- background and the 
Hus1/Atm double mutant mice will be assessed.  I expect that a synthetic lethal 
interaction will be described owing to the cooperative roles of ATM and HUS1 in 
DDR.   
 
38 
In Chapter 3 we test the role for HUS1 in DDR both in physiologic conditions as 
well as after genotoxin treatments.  Due to the current evolving evidence that the 
ATR/CHK1 pathway can be used as a tool to sensitize cancer cells to chemotherapy 
the understanding on how ATR inhibition would affect normal organisms is essential.  
This kind of analysis has been impeded by the severe phenotypes associated with ATR 
deficiency.  Our Hus1 mouse model represents a unique tool for such approaches 
since the Hus1 impaired mice are born at expected frequencies, show no overt 
phenotype, and no increased incidence of cancer formation.  The fact that they have 
increased GIN levels as measured by micronucleus formation prompted us to 
hypothesize that they have enough Hus1 to deal with normal replication stress but will 
become incapable to induce a proper DDR when challenged with genotoxin induced 
replication stress. 
By using this mouse model we will be able to dissect the relationship between the 
ATR and ATM pathways in response to IR treatment.  We hypothesize that Hus1 
deficient mice will show no hypersensitivity to IR but will be hypersensitive to 
replication stress inducing reagents like MMC or HU.  To test these hypotheses Hus1 
impaired mice and wild type littermate controls will be challenged with either IR or 
HU or MMC and the survival post treatment will be assessed.  To further understand 
the role of Hus1 in the different compartments treated mice will be sacrificed at 8 and 
96 hour time points and the pathology of the different organ systems assessed.  
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Moreover to understand the ATM/HUS1 interplay in response to genotoxins 
Atm/Hus1 double mutant mice will be used for similar experiments. 
 Together these data will allow us to create a map for the role of HUS1 in 
development and pathology as well as for the interaction with the ATM pathway.  
Such information will be used in the future for the better understanding of human 
inborn disease and the design of better cancer therapies. 
 
 1 The data in this chapter has been published: Gabriel Balmus, Min Zhu, Sucheta 
Mukherjee, Amy M Lyndaker, Kelly R Hume, Jaesung Lee, Mark L Riccio, Anthony P 
Reeves, Nathan B Sutter, Drew M Noden, Rachel M Peters, Robert S Weiss (2012) - 
Disease severity in a mouse model of Ataxia Telangiectasia is modulated by the DNA 
damage checkpoint gene Hus1 – Human Molecular Genetics 21 (15), 3408-3420 
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 CHAPTER 2 
 
DISEASE SEVERITY IN A MOUSE MODEL OF ATAXIA 
TELANGIECTASIA IS MODULATED BY THE DNA DAMAGE 
CHECKPOINT GENE HUS11 
 
2.1 Abstract 
The human genomic instability syndrome Ataxia Telangiectasia (A-T), caused 
by mutations in the gene encoding the DNA damage checkpoint kinase ATM, is 
characterized by multisystem defects including neurodegeneration, immunodeficiency, 
and increased cancer predisposition. ATM is central to a pathway that responds to 
double strand DNA breaks, while the related kinase ATR leads a parallel signaling 
cascade that is activated by replication stress. To dissect the physiological relationship 
between the ATM and ATR pathways, we generated mice defective for both. Because 
complete ATR pathway inactivation causes embryonic lethality, we weakened the
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ATR mechanism to different degrees by impairing HUS1, a member of the 9-1-1 
complex that is required for efficient ATR signaling. Notably, simultaneous ATM and 
HUS1 defects caused synthetic lethality. Atm/Hus1 double mutant embryos showed 
widespread apoptosis and died mid-gestationally. Despite the underlying DNA 
damage checkpoint defects, increased DNA damage signaling was observed, as 
evidenced by H2AX phosphorylation and p53 accumulation. A less severe Hus1 
defect together with Atm loss resulted in partial embryonic lethality, with the surviving 
double mutant mice showing synergistic increases in genomic instability and specific 
developmental defects including dwarfism, craniofacial abnormalities, and 
brachymesophalangy, phenotypes that are observed in several human genomic 
instability disorders. In addition to identifying tissue-specific consequences of 
checkpoint dysfunction, these data highlight a robust, cooperative configuration for 
the mammalian DNA damage response network and further suggest HUS1 and 
related genes in the ATR pathway as candidate modifiers of disease severity in A-T 
patients. 
2.2 Introduction 
 Ataxia-telangiectasia (A-T, OMIM #208900) is a hereditary genomic instability 
syndrome caused by loss of function mutations in ATM, which encodes a protein 
kinase involved in cellular DNA damage responses (DDR) (McKinnon 2012). A-T is 
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characterized by progressive cerebellar ataxia, oculocutaneous telangiectasias, 
immunodeficiency, infertility, increased cancer incidence, and radiation 
hypersensitivity.  These clinical manifestations are the consequence of failed responses 
to DNA double strand breaks (DSB) that arise spontaneously or as programmed 
developmental events. Rare patients with atypical manifestation of the disease have 
been described and referred to as “A-T variants”. One such variant, termed A-TFresno, 
combines typical A-T phenotypes with microcephaly and mental retardation making it 
among the most severe A-T forms known (Gilad, Chessa et al. 1998). 
 ATM normally functions as the principal component of one of the cellular 
DNA damage checkpoint pathways that detect aberrant DNA structures and 
coordinate DNA repair with cell cycle progression. Checkpoint mechanisms are part 
of a broader DDR that protects genomic integrity and ensures normal development, 
tissue homeostasis, and cancer-free survival (Jackson and Bartek 2009). In response to 
DSB, the ATM kinase undergoes a transition from inactive dimer to active, auto-
phosphorylated monomer and then phosphorylates numerous substrates involved in 
signaling transduction and downstream effector functions, including H2AX, CHK2, 
and p53.  A second checkpoint pathway, organized around the related kinase ATR, 
responds to a wide variety of lesions, including bulky DNA adducts and DNA 
crosslinks, as well as processed DSB. Activated ATR phosphorylates CHK1 and other 
targets, promoting fork stabilization, inhibition of late origin firing, and stimulation of 
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DNA repair (Cimprich and Cortez 2008). Critical for ATR activation is the RAD9-
RAD1-HUS1 (911) complex, a PCNA-like clamp that is loaded onto damage sites and 
recruits the ATR activator TOPBP1 (Kemp and Sancar 2009). Importantly, the 911 
complex additionally has direct roles in regulating base excision repair, translesion 
DNA synthesis, and apoptotic signaling (Helt, Wang et al. 2005). The genes encoding 
the 911 complex, like all ATR pathway core components, are essential for organismal 
survival (Weiss, Enoch et al. 2000; Hopkins, Auerbach et al. 2004; O'Driscoll 2009). 
Partial ATR impairment in humans leads to Seckel syndrome (SCKL1, OMIM 
#210600) an autosomal recessive disorder characterized by proportional dwarfism, 
microcephaly, craniofacial abnormalities and mental retardation (O'Driscoll 2008). 
 Due to their distinct componentry and activation by different types of genome 
damage, the ATM and ATR pathways initially were thought to function as 
independent, separable mechanisms. However, aberrant DNA structures often engage 
both pathways to some extent, and there is substantial biochemical crosstalk between 
the pathways (Cimprich and Cortez 2008). A full appreciation of these interactions in 
vertebrates has been hampered by a lack of suitable genetic tools. While Atm-deficient 
mice are viable and show many A-T phenotypes (Barlow, Hirotsune et al. 1996; 
Elson, Wang et al. 1996; Xu, Ashley et al. 1996), the severe phenotypes associated 
with ATR pathway impairment have been an impediment to understanding the 
biological significance of the interplay between the ATM and ATR pathways. In this 
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study, we overcome this limitation with a Hus1 allelic series in which null (Hus1∆1n) or 
wild-type (Hus1+) alleles are used in combination with a hypomorphic (Hus1neo) allele 
that expresses Hus1 at approximately 20% of the wild-type level (Levitt, Zhu et al. 
2007). Hus1neo/∆1n mice, which have the lowest Hus1 expression in the series, are born 
at expected frequencies and appear grossly normal but are incapable of proper 
genome maintenance as evidenced by increased spontaneous GIN and 
hypersensitivity to exogenous genotoxins (Levitt, Zhu et al. 2007). By combining the 
Hus1 allelic series with targeted Atm deletion, we identify an essential cooperative 
relationship between ATM and HUS1 during embryonic development and in specific 
adult tissues. 
2.3 Material and methods 
Animals. All animals used in this study were handled in accordance with federal and 
institutional guidelines, under a protocol approved by the Cornell University 
Institutional Animal Care and Use Committee (IACUC). Hus1neo and Hus1
1n mice 
were maintained on the 129S6 background (Weiss, Enoch et al. 2000; Levitt, Zhu et al. 
2007). Atm knockout mice were maintained on the FVB background (Elson, Wang et 
al. 1996). These strains were interbred to create Atm/Hus1 double mutant mice. Mice 
were genotyped by PCR analysis of genomic DNA isolated from tail snip biopsies as 
previously described (Weiss, Enoch et al. 2000). Images of live mice and skulls were 
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taken using a Canon EOS Digital Rebel XTi digital camera equipped with a Canon 
EF-S 18-55mm lens. For analysis of embryonic development, timed matings were 
performed. Noon of the day of vaginal plug detection was defined as embryonic day 
E0.5. For analysis of tumor-free survival, a cohort of mice was maintained for up to 
18 months of age or until the appearance of visible neoplasms or signs of clinical 
disease, including weight loss, hunched posture, labored breathing, poor grooming, or 
wasting, at which point they were euthanized by carbon dioxide asphyxiation and 
necropsied. For analysis of radiation sensitivity, mice were subjected to 4Gy or 5Gy 
doses of γ-irradiation using a Mark I Model 68 sealed 137Cs source gamma irradiator 
(JL Shepherd & Associates) and monitored for up to 30 days or until reaching 
humane endpoint criteria based on the clinical disease signs noted above. 
Histology and Immunohistochemistry. Following euthanasia, isolated tissues were weighed 
and then fixed in 10% formalin. Embryos were fixed in 4% paraformaldehyde. 
Histological sections of paraffin-embedded tissues were stained with hematoxylin and 
eosin and subjected to pathological assessment. For assessment of nuclear 
morphology, Feulgen-Schiff staining was carried out using a standard protocol (Weiss, 
Enoch et al. 2000). For immunohistochemistry, E10.5 embryos were embedded in 
paraffin and serial 5 μm sections were collected on Superfrost Plus slides (Fisher) and 
processed for immunohistochemistry using citric acid for p53 or EDTA for γ-H2AX 
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-based antigen retrieval. Sections were incubated with anti-γ-H2AX (Upstate #05-636) 
or p53 (Cell Signalling #2524) antibodies followed by a secondary biotinylated anti-
mouse antibody (Invitrogen, Histostain SP 95-6543B). DAB (DAKO) was used as 
chromogen and hematoxylin as a counter-stain. TUNEL staining was performed 
using the Apoptag (Chemicon International) system according to the manufacturer's 
instructions. More than 1000 cells from at least three 100X fields were counted per 
embryo. Histology images were obtained using an Aperio Scanscope (Aperio 
Technologies, USA). The quantitation was done by counting the distribution of DAB 
positive cells (brown stain) as depicted in Figure S1 D. 
Skeletal morphology and measurements. Micro-computed tomography (CT) scans were 
done on both living mice and isolated specimens using GE CT120 micro-CT (GE 
Healthcare, London, Ontario, Canada) and Xradia VersaXRM-500 (Xradia, 
Pleasanton, CA, USA) scanners. Standard micro-CT scan parameters were used and 
are available upon request. For isolated skull preparations, mice were euthanized and 
decapitated, and heads were de-skinned and boiled in tap water for 20 minutes. Skulls 
were then mechanically cleaned using forceps while the brain was removed by 
flushing with water. Skulls were dried before being stored. For live imaging, mice were 
anesthetized with isoflurane and scanned. In order to accurately measure the distance 
between two points of interest, we developed a tool for marking points on the skull 
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surface in three dimensional (3D) image space. For every marked point, a surface 
coordinate location was computed in mm for x, y, and z 3-D coordinates. The 
distance between any two surface points was computed by using the Euclidean 
distance of the mapped image coordinates. Statistical analysis of the resulting 
morphometry data was performed by a principal component (PC) analysis using the 
princomp() function and a covariance matrix in R 2.6.0. Limbs were isolated after 
euthanasia and subjected to micro-CT imaging as described above. Analysis of the 
resulting data and 3D reconstructions were done using OsiriX software (Rosset, 
Spadola et al. 2004). Skeletal staining with Alcian Blue and Alizarin Red was 
performed as previously described (Kaufman 1992). Briefly, embryos were 
eviscerated, fixed in 80% ethanol for at least 24 hours, dehydrated in 95% ethanol, 
and stained overnight with Alcian Blue (Sigma A3157) in 95% ethanol: 1% glacial 
acetic acid solution. Bone was counterstained with Alizarin Red (Sigma A5533) in 2% 
KOH for 3 hours. Embryos were cleared in a decreasing 2% KOH/glycerol series 
(80:20; 60:40; 40:60) for 24 hours each and stored indefinitely in 2% KOH: glycerol 
(20:80). The stained embryos were imaged using a Leica MZ125 inverse microscope 
equipped with a RT Slider camera (Diagnostic Instruments). 
Micronucleus assay. Analysis of micronucleus (MN) formation in peripheral blood cells 
was performed as previously described (Shima, Hartford et al. 2003; Levitt, Zhu et al. 
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2007). Briefly, peripheral blood was collected from the mandibular vein, fixed in 
methanol, and incubated in bicarbonate buffer containing RNase A and anti-CD71: 
FITC antibody (Biodesign International). After washing and staining with propidium 
iodide, the cells were analyzed on a FACSCalibur flow cytometer (Becton-Dickinson, 
San Jose, CA). 
Cell culture and proliferation measurements. Mouse embryonic fibroblasts (MEFs) were 
prepared from E13.5 embryos following timed matings between Hus1+/neoAtm+/- and 
Hus1neo/neoAtm+/- mice. Briefly, embryos were dissected from the deciduum, 
mechanically disrupted, and cultured in DMEM supplemented with 10% fetal bovine 
serum, 1.0 mM L-glutamine, 0.1 mM minimal essential medium nonessential amino 
acids, 100 µg/ml streptomycin sulfate, and 100 U/ml penicillin. The initial plating was 
defined as passage zero (p0), and cells were subsequently maintained on a 3T3 
protocol (Todaro and Green 1963). Clonogenic potential was assessed by plating 
MEFs in 6 well dishes at 5 x 102 or 3 x 103 cells per well and changing the media every 
3 days. After 11 days in culture, cells were washed with PBS and fixed in methanol for 
one hour at room temperature, stained overnight with a 5% crystal violet solution in 
70% ethanol, and washed with tap water. Immortalized Hus1+/+p21-/- and Hus1-/-p21-/- 
MEFs were described previously (Weiss, Enoch et al. 2000). For IR treatment, cells at 
passage 2 or 3 were exposed to γ-irradiation using a Mark I Model 68 sealed 137Cs 
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source gamma irradiator (JL Shepherd & Associates) at a dose rate of 123.1 Rad/min. 
For UV treatment, the medium was removed from the cells, cells were washed with 
PBS, the top of the culture dish was removed, and the cells were exposed to 254 nm 
UV light using a XL-1000 UV Crosslinker (Spectro Linker).  
 
Metaphase chromosome preparation. Chromosome preparation from mouse embryonic 
fibroblasts (MEFs) from the first passage (P1) followed standard procedures that 
included a 1 hour colcemid  treatment (10 µg/ml; Invitrogen) followed by 6 minutes 
hypotonic incubation (0.075M KCl) and fixation in 3:1 methanol: glacial acetic acid 
(Rens, Fu et al. 2006). At this point cells were dropped onto slides, dried and stained 
with 1:50 Giemsa (Original Azure Blend, Harleco) in Gurr buffer, pH 7. Metaphase 
chromosomes were scored under a 100 (1.6X) oil objective lens according to standard 
guidelines (International Standing Committee on Human Cytogenetic Nomenclature., 
Shaffer et al. 2009). 
 
Northern blotting and real-time PCR. Total RNA was prepared from E10.5 embryos and 
from liver using RNA STAT-60 reagent (Tel-Test, Friendswood, TX) and then 
resolved on a 1% agarose/formaldehyde gel, transferred to a nylon membrane, and 
hybridized with 32P-labeled cDNA probes. Quantification of signal intensity was done 
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using a Storm 860 phosphorimager (Molecular Dynamics , Sunnyvale, USA). Total 
RNA was used for reverse transcription using the SuperScript III kit (Invitrogen) 
according to the manufacturer`s instructions. Quantitative real-time PCR (Q-PCR) 
was performed on an ABI 7500 System (PE Applied-Biosystems) using cDNA as a 
template in the presence of SYBR-green (Quanta Biosciences PerfeCTa SYBR Green 
FastMix). Primer pairs were designed using the Integrated DNA Technologies 
RealTime PCR Assay Design tool (www.idtdna.com) to generate intron-spanning 
products of 150-200bp as follows: Ghr: 5’- AGCCTCGATTCACCAAGTG-3’ and 5’- 
AATTCTTGCAGCTTGTCGTTG -3’; Igf1: 5’- 
GAGACTGGAGATGTACTGTGC-3’ and 5’- CTCCTTTGCAGCTTCGTTTTC-
3’; Gstt2: 5’-TGCCCAAGTCCACGAATAC-3’ and 5’-
CCAGGACCATTCTATCTCTGTTC-3’; Bax: 5’-TTGGAGATGAACTGGACAGC 
-3’ and 5’-CAGTTGAAGTTGCCATCAGC-3’; Puma: 5’-
CTGGAGGGTCATGTACAATCTC-3’ and 5’-GGTGTCAGAAGGCGGAG-3’; 
p21: 5’-CTTGCACTCTGGTGTCTGAG-3’ and 5’-
GCACTTCAGGGTTTTCTCTTG-3’; beta-actin: 5’-ACCTTCTACAATGAGCTGCG 
-3’ and 5’CTGGATGGCTACGTACATGG-3’. The generation of specific PCR 
products was confirmed by melting curve analysis and gel electrophoresis. Each 
primer pair was tested with a logarithmic dilution of cDNA mix to generate a linear 
standard curve, which was used to calculate the primer pair efficiency (Dean Fraga, 
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Tea Meulia et al. 2008). 
Western blotting. Cells were harvested and solubilized in RIPA buffer as described 
previously (Harlow and Lane 2006) or protein was extracted using a high-salt 
extraction procedure (Achari and Lees-Miller 2000). Total protein was quantified by 
Bradford assay, resolved on 6% to 14% SDS-PAGE gels, and subjected to 
immunoblotting using antibodies from Millipore (anti-γ-H2AX, #05-636 and anti-
CHK2, #05-649), Santa Cruz (anti-CHK1, G-4; sc-8408 and anti-p53, FL-393; sc-
6243), Cell Signaling (anti-phospho-CHK1, Ser345, #2341), Rockland (anti-ATM, 
pSer1981, 200-310-400) and Sigma (anti-beta actin, #A5441). Western-blot imaging 
and quantification was performed using a Versa Doc Imaging System (Bio-Rad 
Laboratories). 
 
2.4 Results 
2.4.1 Combined inactivation of Atm and Hus1 results in synthetic lethality.  
To elucidate the genetic relationships between the ATM- and ATR-mediated 
DNA damage checkpoint pathways, we generated mice defective for both. 
Interbreeding of mice bearing targeted Atm and Hus1 alleles was performed in order 
to produce Atm-deficient mice with incremental reductions in Hus1 gene dosage 
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(Hus1+/+ > Hus1+/neo > Hus1+/Δ1n > Hus1neo/neo > Hus1neo/Δ1n). Hus1+/neo cells and mice 
are phenotypically normal and frequently used as wild-type equivalents in this study 
(Levitt, Zhu et al. 2007). Of 1753 weaned offspring analyzed, no Hus1neo/Δ1nAtm-/- mice 
were obtained, and only 84 Hus1neo/neoAtm-/- mice were obtained while 259 were 
expected (Table 2.1; p<0.001 Chi-square test). The nature of the lethal phenotype 
associated with combined Atm and Hus1 inactivation was determined by analyzing 
double mutant and control embryos from embryonic day E8.5 to birth (Table 2.2). 
While Hus1neo/Δ1nAtm-/- embryos appeared normal at E8.5, they were smaller relative to 
their littermates at E9.5 and all died between E10.5 and E11.5 (Figure 2.1A-D). A less 
severe Hus1 defect in Hus1neo/neoAtm-/- embryos resulted in no gross abnormalities prior 
to E13.5, at which point the double mutant embryos were smaller than their 
littermates. Approximately 30% of Hus1neo/neoAtm-/- embryos were abnormal at E14.5 
and died by E15.5 (Figure 2.1E-H). Hus1neo/neoAtm-/- mice that survived beyond this 
mid-gestational period were significantly smaller than control littermates  
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Table 2.1. Synthetic lethality following combined impairment of Hus1 and Atm 
in micea. 
Hus1 genotype Atm genotype Number expected Number observed 
+/+  3 5 
+/neo  95 108 
+/Δ1n +/+ 12 9 
neo/neo  259 286 
neo/Δ1n  69 58 
+/+  6 5 
+/neo  190 208 
+/Δ1n +/- 24 31 
neo/neo  518 659 
neo/Δ1n  138 190 
+/+  3 4 
+/neo  95 93 
+/Δ1n -/- 12 13 
neo/neo  259 84 
neo/Δ1n  69 0 
  1753 1753 
a Mice were genotyped by PCR analysis of tail DNA at 3 weeks of age. Expected 
values represent the combined Mendelian ratios from several crosses involving 
different parental genotypes (p<0.001; Chi-square test)  
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Table 2.2. Genotype and phenotype analysis of embryos from interbreedings of Hus1 and Atm mutant mice a 
  
Genotype E8.5 E9.5 E10.5 E11.5 E12.5 E13.5 
Hus1 Atm E O P E O P E O P E O P E O P E O P 
+/+                    
+/neo     2 1        1 0  7 5  
+/Δ1n +/+    2 2           1 1  
neo/neo  6 5 2a 20 21  19 21 2a 8 7  5 2  7 8  
neo/Δ1n  6 3  8 13  13 13  8 7  4 2  1 0  
+/+                    
+/neo     4 5        2 2  15 15  
+/Δ1n +/-    4 4           1 2  
neo/neo  12 15 1a 40 37 3a 37 32  15 16  10 14  15 15  
neo/Δ1n  12 10  15 17  27 38 4a 15 19  8 14 1a 1 1  
+/+                    
+/neo     2 5        1 1  7 8  
+/Δ1n -/-    2 0           1 1  
neo/neo  6 6 1a 20 14 2a 19 13 2a 8 5  5 4  7 7  
neo/Δ1n  6 9  8 7 7a 13 10 10a 8 6 6d 4 0  1 0  
TOTAL  30 30  126 126 1r 127 127  60 60 4r 39 39 9r 63 63 4r 
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a Embryos from timed matings were isolated at the indicated time post coitum and genotyped by PCR analysis of yolk 
sac DNA. The observed (O) values were compared to expected (E) values based on the normal Mendelian ratios for 
several crosses involving different parental genotypes. Any abnormal phenotypes (P) were noted. Embryos that were 
small in size, developmentally delayed, or morphologically aberrant but had a beating heart was classified as abnormal 
(a), while embryos without a heartbeat were classified as dead (d). The rows marked ‘TOTAL’ also indicate the number 
resorbed embryos that could not be genotyped (r). 
Genotype E14.5 E15.5 E16.5 E17.5 E18.5 P1 
Hus1 Atm E O P E O P E O P E O P E O P E O P 
+/+                    
+/neo  8 7  2 3  3 1  3 3  7 6  9 10 1d 
+/Δ1n +/+       1 0  1 2        
neo/neo  15 13  9 8  9 11  9 9  9 13  26 25  
neo/Δ1n  3 3  5 6  4 6  7 11  2 2  5 7  
+/+                    
+/neo  15 19  5 2  5 5  5 6  14 15 1a 19 22 1a 
+/Δ1n +/-       1 0  1 1        
neo/neo  30 30  18 18  17 19  18 21  18 20  53 59 1d 
neo/Δ1n  6 8  11 17  8 7  14 14  5 4  11 13  
+/+                    
+/neo  8 5  2 3  3 5 2a 3 3  7 7  9 8  
+/Δ1n -/-       1 1 a 1 0        
neo/neo  15 17 
9a 
5d 
9 10 
7a 
2d 
9 8 
4a 
4d 
9 5 5a 9 6 6a 26 20 
8a 
12d 
neo/Δ1n  3 0  5 0  4 0  7 0  2 0  5 0  
TOTAL  102 102 5r 67 67 5r 63 63 4R 75 75 4r 73 73 2r 164 164  
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Figure 2.1. Embryonic lethality upon simultaneous deregulation of Atm and 
Hus1. Embryos from timed matings were isolated at the indicated stage of embryonic 
development, imaged for morphological assesment and genotyped by PCR. (A-D) 
Representative images of Hus1neo/Δ1nAtm-/- embryos and control littermates from E8.5 
to E11.5. (E-F) Representative images of Hus1neo/neoAtm-/- embryos and control 
littermates from E13.5 to E16.5. Note that at E14.5 some Hus1neo/neoAtm-/- embryos are 
dead whereas others are smaller than control littermates but otherwise normal. 
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(Figure 2.4 A,B; p<0.05 Student’s t test), and 30-40% of mice of this genotype died on 
the first day of life (P1) (Table S1), while the remainder survived beyond weaning 
(Table 2.1). Together, these data indicate that although defects in Atm or Hus1 
individually are compatible with grossly normal development and organismal viability, 
simultaneous defects in Atm and Hus1 cause synthetic lethality in a Hus1 gene dosage 
dependent manner. 
2.4.2 Increased genomic instability and cell death in Atm/Hus1-deficient 
embryos.  
 The failure of cells to deal with replication stress and spontaneous DNA 
lesions can lead to impaired cell proliferation and/or survival (Bartek, Lukas et al. 
2004). To evaluate these outcomes in Atm/Hus1 mutant embryos, we initially 
performed Feulgen-Schiff staining on E10.5 embryos and quantified the frequency of 
pyknotic and mitotic nuclei. There was a significant increase in pyknotic nuclei 
indicative of apoptosis in Hus1neo/∆1nAtm-/- and Hus1neo/neoAtm-/- embryos as compared 
to the Hus1+/neoAtm+/+ control group (Figure 2.2, p<0.001; Student’s t test). By 
contrast, cell proliferation was unaffected. We reasoned that the apparent increase in 
apoptosis in the Atm/Hus1 double mutants could be due to checkpoint activation and 
therefore monitored the accumulation of phosphorylated H2AX (γ–H2AX) and total 
p53, markers of an activated DDR (Jackson and Bartek 2009). Terminal uridine 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining also was   
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Figure 2.2. Significant increase in apoptosis but no change in proliferation in 
Atm/Hus1 double mutant embryos. Representative sections of Feulgen-Schiff 
staining of A) Hus1+/neoAtm+/+ and B) Hus1neo/∆1nAtm-/- embryos at E10.5. Right panels: 
higher magnification view of neural tube showing representative apoptotic (red arrow 
head) and mitotic (black arrow head) figures. Scale bar represents 25µm. C) Values 
indicate the percent of apoptotic and mitotic cells (± standard deviation) as 
determined from Feulgen-Schiff stained sections of embryos of the indicated 
genotypes. Student’s t-test identified a significant increase in apoptosis (p<0.001) in 
both Hus1neo/∆1nAtm-/- (n=3) and Hus1neo/neoAtm-/- (n=5) but no change in proliferation 
when compared to Hus1+/neoAtm-/- (n=3). D) Representative γ-H2AX 
immunohistochemistry images for E8.5 Hus1+/+ embryos with no treatment or after 
5Gy IR treatment. Read arrows point to positive staining. 
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Figure 2.3. Significantly increased apoptosis and DDR activation in Atm/Hus1 
double mutant embryos. Sections of E10.5 Atm/Hus1 embryos of the indicated 
genotypes were stained for γ-H2AX, p53, or by TUNEL assay. A) Representative 
images of embryo neural tube sections stained for γ-H2AX, p53 and TUNEL are 
shown. Scale bar represents 25µm. B) Percentage of γ-H2AX, TUNEL or p53 
positive cells. Values are the mean of at least three embryos per genotype; error bars 
indicate standard deviation. Quantification was performed in neural ectoderm to 
ensure that equivalent cell populations were compared between genotypes; however 
similar staining patterns were observed throughout the embryos, irrespective of cell 
type. The percentage of positively stained cells in Hus1neo/Δ1nAtm-/- and Hus1neo/neoAtm-/- 
embryos was significantly different from each other (p<0.05; Student’s t-test) and 
when each was compared to all the other genotypes (p<0.01, Student’s t-test). C) Bar 
graph representing the fold increase in expression level of p21, Bax, and Puma for 
embryos of the indicated genotype relative to Hus1+/neoAtm+/+ as measured by qPCR. 
p21 expression was significantly increased in Hus1neo/∆1nAtm+/+, Hus1+/neoAtm-/-, 
Hus1neo/neoAtm-/-, and Hus1neo/∆1nAtm-/- embryos (p<0.05; Student’s t-test) and was 
significantly greater in Hus1neo/∆1nAtm-/- embryos as compared to all other genotypes 
(p<0.05; Student’s t-test). 
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performed to directly measure apoptosis. While almost no γ-H2AX, p53, or TUNEL-
positive cells were detected in Hus1 or Atm single mutant embryos, Hus1neo/neoAtm-/- 
and to an even greater extent Hus1neo/∆1nAtm-/- littermates showed significantly 
increased positive staining (Figure 2.3A, B; p<0.05; Student’s t test). Because p53 can 
induce cell cycle arrest through transcriptional activation of p21 or apoptosis by 
upregulating Bax and Puma, we used real-time PCR to measure the expression level of 
these genes in E10.5 embryos. Consistent with the observation of p53 accumulation 
in Atm/Hus1 double mutant embryos, there was a corresponding significant increase 
in p21 expression (Figure 2.3 C; p<0.05 Student’s t test). Interestingly, there were no 
detectable changes in Bax or Puma expression, raising the possibility of a p53-
independent apoptotic mechanism. Similar results were observed by Northern blot 
analysis (data not shown). Altogether, these findings suggest that the embryonic 
lethality following combined deregulation of Atm and Hus1 is associated with a 
generalized accumulation of genome damage, activation of a DDR, and ultimately 
widespread apoptosis. 
2.4.3 Dwarfism in adult Hus1neo/neoAtm-/- mice.  
  Approximately one-third of Hus1neo/neoAtm-/- mice survived to adulthood, and 
without exception these animals exhibited a striking dwarfism that became apparent at 
approximately E13.5 and persisted through adulthood (Figure 2.4 A-D). Consistent   
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Figure 2.4. Relative brain size in Hus1neo/neoAtm-/- and littermate control mice. 
A) Brains dissected from 6-week old littermate male mice of the indicated genotypes 
are shown. Scale bar represents 5 mm. B) Box plot shows the percent weight of the 
brain relative to total body weight for mice of the indicated genotypes at 6 weeks of 
age. The brain weight of Hus1neo/neoAtm-/- mice (n=5) was significantly different from 
that of Hus1+/neoAtm+/+ (n=3) (*p<0.009; Student’s t-test), Hus1neo/neoAtm+/+ (n=3) 
(*p<0.001; Student’s t-test) and Hus1+/neoAtm-/- (n=4) (*p<0.03; Student’s t-test) mice. 
C) Representative Hematoxylin and Eosin (upper panels) and Bielschowsky silver 
(lower panels) stained sequential sections of corpus callosum from mice of the 
indicated genotypes. Scale bar represents 50µm. 
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Figure 2.5. Dwarfism in Hus1neo/neoAtm-/- embryos and adult mice. A) Box plot 
indicates the body weight of E18.5 embryos of the indicated genotypes (n≥4 per 
group). Hus1neo/neoAtm-/- embryos were significantly smaller than their littermates 
(p<0.001, Student’s t-test). B) Representative image of newborn (P1) littermates of 
the indicated genotypes is shown. Scale bar represents 5 mm. C) Photograph of 6-
week old male littermates of the indicated genotypes. D) Body weight analysis of 
Hus1neo/neoAtm-/- mice and control littermates. The average body weights of female mice 
(n≥5) of the indicated genotypes, from weaning to 9 weeks of age, are shown. The 
mean body weight was significantly lower for Hus1+/neoAtm-/- mice as compared to the 
Atm+/+ groups (*p<0.05; Mixed Model Analysis); Hus1neo/neoAtm-/- mice had 
significantly lower mean body weight as compared to all other groups (**p<0.01; 
Mixed Model Analysis). E) Northern blot analysis of transcript levels of Igf1 and Ghr 
in total RNA from liver. Gapdh was used as a loading control. 
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Table 2.3. Organ weight in Hus1neo/neoAtm-/- and littermate control mice a  
 
a Mice were sacrificed at 6 weeks of age and the indicated organs were weighed. 
b Values represent percent organ weight relative to total body weight ± standard 
deviation. Relative brain mass was greater in the Hus1neo/neoAtm-/- mice (*p<0.05) as 
compared to all other groups. A significant difference also was apparent for cerebrum 
alone (†p<0.005), whereas the cerebellum was relatively larger in both Hus1neo/neoAtm-/- 
(‡p<0.006) and Hus1+/neoAtm-/- (‡‡p<0.03) mice as compared to Hus1neo/neoAtm+/+ 
animals. Testis weight was relatively lower for both Hus1+/neoAtm-/- and 
Hus1neo/neoAtm-/- mice as compared to all other genotypes (#p<0.001). Statistical 
analysis was performed by Student’s t-test. 
c Hus1+/neoAtm+ refers to the mean for Hus1+/neoAtm+/+ (n=3) and Hus1+/neoAtm+/- 
(n=3) control littermates. 
  
Relative organ weight (%) b 
Genotype 
Hus1+/neoAtm+ c Hus1neo/neoAtm+/+ Hus1+/neoAtm-/- Hus1neo/neoAtm-/- 
(n=6) (n=7) (n=5) (n=7) 
Total Brain  2.1 ± 0.3% 2.0 ± 0.3% 2.2 ± 0.3% 2.6 ± 0.3%* 
Cerebrum 1.4 ± 0.2% 1.4 ± 0.2% 1.5 ± 0.2% 1.8 ± 0.2%† 
Cerebellum 0.6 ± 0.1% 0.5 ± 0.1% 0.7 ± 0.2%‡‡ 0.7 ± 0.1%‡ 
Spleen 0.5 ± 0.2% 0.4 ± 0.1% 0.4 ± 0.1% 0.3 ± 0.1% 
Liver 5.4 ± 0.1% 5.6 ± 0.4% 5.6 ± 0.8% 6.1 ± 0.5% 
Kidney 0.7 ± 0.1% 0.8 ± 0.1% 0.7 ± 0.1% 0.8 ± 0.1% 
Thymus 0.5 ± 0.2% 0.5 ± 0.2% 0.4 ± 0.1% 0.5 ± 0.1% 
Testis 0.4 ± 0.1% 0.4 ± 0.1% 0.1 ± 0.1%# 0.2 ± 0.1%# 
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with previous reports (Barlow, Hirotsune et al. 1996; Elson, Wang et al. 1996; Xu, 
Ashley et al. 1996), modestly reduced body size was observed in Hus1+/neoAtm-/- mice 
defective for Atm alone (p<0.05; Mixed model analysis). This phenotype was 
significantly enhanced in Hus1neo/neoAtm-/- animals, which on average were 40% smaller 
by weight than control littermates at 6 weeks of age (Figure 2.5 D; p<0.01; Mixed 
model analysis). Most organs were proportionally smaller in both Hus1+/neoAtm-/- and 
Hus1neo/neoAtm-/- mice as compared to Hus1+/neoAtm+/+ controls (Table 2.3). 
Hus1neo/neoAtm-/- mice showed a slight increase in relative brain size as compared to 
mice of all other genotypes, but this was not associated with any apparent 
histopathological abnormalities (Figure 2.4). 
It is well established that the somatotroph axis that includes growth hormone 
(GH) and insulin-like growth factor 1 (IGF1) plays important roles in somatic growth 
and aging (Lupu, Terwilliger et al. 2001). Deficiencies in the GH/IGF1 somatotroph 
axis are observed in some mouse mutants that display dwarfism in conjunction with 
underlying DDR defects (Niedernhofer 2008). In order to understand the molecular 
basis for the dwarfism in Atm/Hus1 mutant mice we analyzed the expression levels of 
Igf1 and Ghr and found no difference in their transcript levels in livers of 6-week old 
mice of representative genotypes (Figure 2.5E), findings that were confirmed by 
qPCR (data not shown). Furthermore, preliminary analyses revealed no differences in 
circulating IGF1 levels in Hus1neo/neoAtm-/- mice relative to controls (data not shown). 
Overall these results demonstrate that combined Hus1 and Atm deficiency has a   
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Figure 2.6. Skeletal abnormalities in Hus1neo/neoAtm-/- embryos and adult mice. 
A) Shown is a representative image of Alizarin red-Alcian blue stained skulls from 
E18.5 littermates of the indicated genotypes. Dotted lines outline the region where the 
skull plates have yet to fill in and fuse. The arrowhead indicates the fenestrations 
present in the Hus1neo/neoAtm-/- skull. B) Skulls were prepared from 6-week old 
littermates of the indicated genotypes and photographed. The arrowhead indicates the 
fenestrations present in the parietal bone. The arrow indicates abnormal sutures of the 
mutant. Lower panels: higher magnification view of sutures in the Hus1neo/neoAtm-/- 
(left) and Hus1+/neoAtm-/- (right) skulls. C) A representative image of the skulls from 6 
week old littermates of the indicated genotypes is shown. The outline was generated 
in Photoshop to illustrate the doming of the skull. D, E) 3D reconstructions based on 
micro-CT data for forelimbs (D) or hindlimbs (E) from Hus1neo/neoAtm-/- and 
Hus1+/neoAtm-/- mice, and bar graphs of the corresponding measurement data (n=3 per 
genotype). Red arrowheads point to the mesophalanx of digit V. The relative length 
of mesophalanx V in both forelimbs and hindlimbs was significantly shorter in 
Hus1neo/neoAtm-/- mice as compared to all other genotypes (*p<0.001; Student’s t-test). 
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Figure 2.7. Skeletal abnormalities in Hus1neo/neoAtm-/- mice. A) Littermate 
embryos of the indicated genotypes at E15.5 were stained with Alizarin Red and 
Alcian Blue. Arrow heads indicate the incomplete closure of the head bones and the 
presence of fenestrations. The dotted lines outline the head bones and highlight the 
incomplete development in Hus1neo/neoAtm-/- as compared to Hus1+/neoAtm-/- embryos. 
B) Limbs of littermate embryos of the indicated genotypes at E15.5 were stained with 
Alizarin Red and Alcian Blue. Red arrow heads indicate the mesophalanx of the fifth 
digit. Insets show magnified views of the fifth digit in black and white. C) Limbs of 
littermate embryos of the indicated genotypes at P10 were stained with Alizarin Red 
and Alcian Blue. Red arrow heads indicate the mesophalanx of the fifth digit. D) A 
schematic of the dorsal aspect of the mouse skull is shown (top). The landmark points 
used for the analysis are numbered. Representative measurements were chosen for the 
analysis as follows: 1-2 Nose length; 1-6 Skull length; 2-4 Naso-parietal length; 2-6 
Naso-occipital length; 4-5 Interparietal length; 7-12 Skull width; 8-13 Intersquamosal 
distance; 9-14 Interzygomatic distance; 10-15 Intercanthal distance; 11-16 Face width; 
13-14 Zygomatic length; 14-15 Premaxilo-zygomatic distance; 15-16 Premaxili-maxilo 
distance; 16-18 Maxilo-frontal length; 17-18 Frontal width. Image modified from 
(Cook 1965) with permission from Elsevier. Visualization of the marked surface 
points is shown on a 3D reconstruction of micro-CT images of a Hus1+/neoAtm+/+ 
mouse skull (bottom). The distance between any two surface points was then 
computed using Euclidean distance of the mapped image coordinates as described in 
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Material and Methods. E) Principal component 1 (PC1) scores for each individual 
mouse (filled circles) shown as boxplots by genotype (n ≥ 5 for each genotypic class). 
The Hus1neo/neoAtm-/- skulls differed significantly from all other genotypes along the 
PC1 axis (p<0.0001; Student’s t-test). Hus1+/neoAtm-/- skulls were significantly smaller 
than those of Hus1neo/neoAtm+/+ mice (p<0.05, Student’s t-test). F) Factor loadings for 
principal component one. Bars indicate the correlations and inverse correlations (17-
18, 4-5) between individual measurements and PC1. The pattern of variation captured 
by PC1 is a combination of both change in overall skull size and shape: the skulls of 
the Hus1neo/neoAtm-/- were smaller overall but their interparietal lengths (4-5) and frontal 
widths (17-18) are larger. The PC analysis was repeated excluding the Hus1neo/neoAtm-/- 
samples and no differences were observed.  
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severe impact on body size from mid-gestation to adulthood and that this 
proportional dwarfism arises independently of detectable abnormalities in the 
somatotroph axis. 
2.4.4 Skeletal abnormalities in Hus1neo/neoAtm-/- mice.  
  Visual inspection of Hus1neo/neoAtm-/- mice also revealed fronto-parietal alopecia 
and an abnormal facial morphology (Figure 2.5C). To understand the origins of these 
abnormalities, we performed Alizarin-red/Alcian-blue staining of embryos. At E18.5, 
Hus1neo/neoAtm-/- embryos had widely open sagittal (midline) sutures and presented an 
array of fenestrations primarily in the parietal bone (Figure 2.6A) that also were 
apparent as early as E15.5 (Figure 2.7A). In order to characterize the craniofacial 
defects in adult animals, we first produced isolated skull preparations from mice at 6 
week of age. Grossly, Hus1neo/neoAtm-/- skulls showed a domed morphology with 
incomplete closure of the sagittal sutures and reduced bone thickness in the fronto-
parietal region, multiple fenestrations in the parietal bone and jagged coronal (fronto-
parietal) sutures (Figure 2.6 B, C). To identify and quantify patterns in skull 
morphology, we analyzed high resolution three-dimensional images generated by 
micro-computed tomography (micro-CT) (Figure 2.7 D). A series of measurements 
were then subjected to principal component (PC) analysis to identify suites of changes 
in skull morphology. The first PC by itself explained 83.6% of the variance in the 23 
skull measurements and therefore in a single number captured the significant variation 
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between Hus1neo/neoAtm-/- samples and those of Hus1+/neoAtm+/+, Hus1neo/neoAtm+/+, and 
Hus1+/neoAtm-/- genotypes (Figure 2.7 E). The correlations or factor loadings between 
the PC1 score and each distance measured for each mouse further resolved the 
pattern of variation: the skulls of Hus1neo/neoAtm-/- mice were smaller overall and 
differed in shape, with an elongated inter-parietal bone and a wider frontal bone, 
which increased the inter-orbital distance (Figure 2.7 F).  
 Detailed analysis of the embryonic skeletal preparations also revealed 
brachymesophalangy of the fifth digit (Figure 2.7 B, C). Interestingly, this and the 
related phenotype of clinodactyly are associated with several hereditary GIN 
syndromes, other congenital disorders, and fetal teratogen exposure (Rypens, Dubois 
et al. 2006). Further inspection of micro-CT images indicated that the phalangeal 
defect was fully penetrant in adult Hus1neo/neoAtm-/- mice and affected both the 
forelimbs and hindlimbs (Figure 2.6 D, E). Quantitative measurements showed that 
the mesophalanx of the fifth digit was less than one-half of the expected size in 
Hus1neo/neoAtm-/- mice relative to controls, whereas the remaining digits were unaffected 
(p<0.001; Student`s t test). Considered together with the craniofacial defects 
described above, these results demonstrate an essential dual function for Atm and 
Hus1 in the development of the skeleton and suggest a potential elevated sensitivity of 
particular bone progenitor cells to checkpoint impairment and genomic instability. 
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2.4.5 Increased genomic instability in adult mice defective for both Atm and 
Hus1.  
 HUS1 and ATM are integral components of DNA damage signaling pathways 
that function to protect genomic integrity. We therefore tested the impact of 
combined Atm and Hus1 defects on GIN in adult mice by measuring micronucleus 
(MN) formation in peripheral blood cells using a flow cytometry based assay. MN are 
entire chromosomes or fragments of chromosomes that have not been incorporated 
in the main nuclei at cell division and are a hallmark of GIN. Consistent with previous 
findings (Shima, Hartford et al. 2003; Levitt, Zhu et al. 2007), a moderate Hus1 defect 
alone in Hus1neo/neoAtm+/+ mice caused no significant change in MN formation relative 
to Hus1+/neoAtm+/+ littermate controls, whereas Atm deficiency alone was associated 
with significantly increased MN formation in Hus1+/neoAtm-/- mice (Figure 2.8 A; 
p<0.001; Student’s t test). Notably, Hus1neo/neoAtm-/- mice had more than an additive 
increase in MN formation when compared to Hus1neo/neoAtm+/+ and Hus1+/neoAtm-/- 
animals (p=0.002; Univariate Analysis of Variance). By contrast, expression of damage 
inducible genes such as p21 was unaltered in adult liver, a relatively quiescent tissue 
(Figure 2.9). These observations suggest that phenotypes associated with combined 
Atm and Hus1 defects in adult mice may be more pronounced in proliferating cell 
populations such as blood cell precursors and highlight a potential role for replication 
stress as a key factor in the observed genetic interaction.   
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Figure 2.8. Increased genomic instability with no change in tumor 
predisposition in Hus1neo/neoAtm-/- mice. A) Bar graph shows the average 
percentage of peripheral blood cells with micronuclei in mice of the indicated 
genotypes. Hus1neo/neoAtm+/+ and Hus1+/neoAtm+/+ mice showed similar levels of GIN 
while Hus1+/neoAtm-/- mice had a significant increase in micronucleus formation 
(p<0.001; Student’s t test). The combined effect of Hus1 impairment in an Atm null 
background (Hus1neo/neoAtm-/-) resulted in a greater than additive increase in GIN 
(p=0.002; Univariate Analysis of Variance). B) Bar graph shows the relative number 
of thymocytes in 6-week old mice of the indicated genotypes (n≥3 per group) 
expressed as a percentage of the value for Hus1+/neoAtm+/+ control littermates. Error 
bars indicate standard deviation. The entire thymus from each mouse was harvested 
and mechanically disrupted, and viable trypan blue negative thymocytes were counted 
using a hemocytometer. The relative number of thymocytes was significantly lower 
for both Hus1+/neoAtm-/- and Hus1neo/neoAtm-/- mice (*p<0.001; Student’s t-test). C) 
Representative Hematoxylin and Eosin stained sections of thymic lymphomas from 
Hus1+/neoAtm-/- (left) and Hus1neo/neoAtm-/- (right) mice. Scale bar represents 50µm. D) 
Cohorts of Hus1neo/neoAtm-/- (n=41) and Hus1+/neoAtm-/- (n=43) mice were monitored 
for tumor development as described in Material and Methods. A Kaplan-Meier 
survival curve is shown. Overall survival was not significantly different between 
genotypes (p=0.644, log-rank test) 
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Figure 2.9. Liver transcript analysis in Hus1/Atm double mutant and control 
mice. Bar graph shows the fold expression level of p21, Bax, and Gstt2 in liver 
samples (n=3) from mice of the indicated genotypes relative to Hus1+/neoAtm+/+. No 
significant differences were detected.  
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Table 2.4. Blood composition in Hus1neo/neoAtm-/- and littermate control mice a 
a Blood was collected from 6-week old mice by mandibular bleeding into EDTA containing 
tubes (Hoff 2000) and sent to Cornell Animal Health Diagnostic Center. 
b Hus1+Atm+ refers to the mean for Hus1+/neoAtm+/+ (n=1), Hus1+/neoAtm+/- (n=2), 
Hus1neo/neoAtm+/+ (n=1) and Hus1neo/neoAtm+/- (n=1) mice.  
c The only statistically significant differences observed were between Atm-/- (both 
Hus1+/neoAtm-/- and Hus1neo/neoAtm-/-) and Atm+ mice (p < 0.05; Student’s t-test). Values are 
consistent with previously reported blood composition data for wild-type and Atm-deficient 
mice (Barlow, Hirotsune et al. 1996; Elson, Wang et al. 1996; Xu, Ashley et al. 1996; Wirth-
Dzieciolowska, Karaszewska et al. 2009).  
Test 
Hus1+Atm+ b 
(n=5) 
Hus1+/neoAtm-/- 
(n=4) 
Hus1neo/neoAtm-/- 
(n=4) 
Units 
Hematocrit 49.2 ± 3.6 48.0 ± 3.9 45.3 ± 7.8 % 
Hemoglobin 14.7 ± 0.8 15.1 ± 1.2 13.7 ± 2.0 g/dL 
Red Blood Cells (RBC) 9.0 ±1.9 9.4 ± 0.7 8.9 ± 1.5 mill/µL 
Mean cell volume (MCV) 51.4 ± 3.4 51.0 ± 1.6 51.0 ± 1.4 fL 
Mean corpuscular 
hemoglobin (MCH) 
15.6 ± 0.5 16.0 ± 0 15.5 ± 0.6 
pg 
Mean corpuscular 
hemoglobin concentration 
(MCHC) 
30.2 ± 2.3 31.8 ± 0.5 30.5 ± 1.0 
g/dL 
Red blood cell distribution 
width (RDW) 
13.0 ± 0.7 12.9 ± 0.6 13.5 ± 0.8 
% 
White Blood Cells (WBC) 6.7 ± 0.3 4.7 ± 3.2 5.1 ± 2.8 thou/µL 
Platelet Count 1477 ± 193.5 1368.3 ± 509.2 1149.7 ± 516.1 thou/µL 
Mean Platelet Volume 
(MPV) 
8.2 ± 1.0 8.7 ± 1.0 8.5 ± 1.6 
fL 
Segmented Neutrophil(s) 0.7 ± 0.4 1.7 ± 2.0 1.8 ± 1.8 thou/µL 
*Lymphocyte(s) 5.6 ± 0.2 2.3 ± 0.9c 2.5 ± 1.1c thou/µL 
Monocyte(s) 0.2 ± 0.1 0.2 ± 0.1 0.3 ± 0.2 thou/µL 
Eosinophil(s) 0.2 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 thou/µL 
Basophil(s) 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 thou/µL 
Large Unstained Cell(s) 0.1 ± 0.1 0.2 ± 0.2 0.3 ± 0.1 thou/µL 
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 Increased GIN may influence different steps en-route to carcinogenesis, including 
tumor initiation and progression, and in Atm-null mice contributes to the 
development of thymic lymphoma with near complete penetrance (Barlow, Hirotsune 
et al. 1996; Elson, Wang et al. 1996; Xu, Ashley et al. 1996). Prior to tumor 
development, Hus1neo/neoAtm-/- and Hus1+/neoAtm-/- mice contained similar numbers of 
lymphocytes in the thymus (Figure 2.8 B) and circulating blood (Table 2.4) and 
subsequently showed no significant difference in tumor-free survival as determined by 
Kaplan-Meier survival analysis (Figure 2.8 D). Furthermore, the resulting neoplasms 
were indistinguishable histopathologically (Figure 2.8 C). Together, these results reveal 
that combined defects in Atm and Hus1 result in synergistic increases in GIN in adult 
mice but without major consequences on thymic tumorigenesis. 
2.4.6 Partial Hus1 impairment synergizes with Atm deficiency to accelerate 
senescence without detectably altering key DNA damage checkpoint signaling 
events or radiation sensitivity. The strong genetic interaction observed between 
Atm and Hus1 raised the possibility of overlapping roles for these checkpoint proteins 
in DNA damage signaling. Complete Hus1 inactivation results in impaired activation 
of the ATR substrate CHK1 but does not diminish induction of the ATM substrates 
CHK2 or p53 (Weiss, Matsuoka et al. 2002). Consistent with the prevailing view that 
ATM activation occurs independently of the 911 complex, we observed that IR- or 
UV-induced ATM phosphorylation occurred to a similar or greater extent in Hus1-
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null cells as compared to Hus1-proficient controls (Figure 2.10A). To better 
understand the relationship between Hus1 and Atm at the cell and molecular levels, we 
isolated primary mouse embryonic fibroblasts (MEFs) from the Atm/Hus1 mouse 
model and analyzed their behavior in culture. Consistent with previous results (Xu and 
Baltimore 1996; Levitt, Zhu et al. 2007), Atm-deficient Hus1+/neoAtm-/- MEFs 
underwent senescence prematurely whereas Hus1neo/neoAtm+/+ MEFs doubled in a 
manner similar to Hus1+/neoAtm+/+ control cells. The combination of Atm and Hus1 
defects in Hus1neo/neoAtm-/- MEFs resulted in extremely rapid senescence after just a few 
doublings (Figure 2.11A). Chromosome analysis at the first passage revealed increased 
frequency of chromosomal abnormalities in Hus1neo/neoAtm+/+ single mutant cells when 
compared to Hus1+/neoAtm+/+ cells (p<0.05; Student’s t test). ATM deficiency in 
Hus1+/neoAtm-/- and Hus1neo//neoAtm-/- cell lines resulted in increased number of 
abnormalities (p<0.05 Student’s t test) with the Hus1/Atm double mutants having a 
significant increase in extensive chromosomal damage (p<0.01; Student’s t test) as 
well as an increased frequency in radial figures (p<0.05; Student’s t test) when 
compared to Atm-/- single mutant alone (Figure 2.12). Nevertheless, cells of all 
genotypes were capable of undergoing spontaneous immortalization, after which they 
doubled at similar rates when maintained under standard 3T3 culture conditions, both 
in low (3%) (data not shown) and normal (20%) O2 levels (Figure 2.11A). The 
proliferative capacity of the spontaneously immortalized Atm/Hus1 MEFs was 
analyzed under more stringent conditions by plating cells at low density and assessing   
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Figure 2.10. DNA damage signaling in Atm/Hus1 double mutant mouse 
embryonic fibroblasts. A) Immortalized MEFs of the indicated genotypes were 
treated with 20Gy IR or 65J/m2 UV, and total protein lysates were prepared at 0, 2 
and 8 hours post-treatment. Samples were immunoblotted using antibodies specific 
for phospho-Ser1981-ATM, or Beta actin as a loading control. Similar results were 
obtained with an independent set of Hus1-/-p21-/- and matched control Hus1+/+p21-/- 
MEFs (data not shown). B) Primary MEFs at passage 1 or 2 were treated with 30Gy 
IR or 65J/m2 UV and total cell protein lysates were prepared at 0, 2, 8 and 24 hours 
post-treatment and immunoblotted for CHK1, phosphoSer345-CHK1, CHK2 and 
p53. Arrow indicates the position of phosphorylated CHK2. Beta-actin was used as a 
loading control. C) Kaplan-Meier survival curves show the radiation sensitivity of 
mice of the indicated genotypes following exposure to 4Gy (left) or 5Gy (right) IR. 
The cohort treated with 4Gy included Hus1+/neoAtm+ (n=7; Atm+ is a combination of 
Atm+/+ and Atm+/-), Hus1neo/neoAtm+/+ (n=6), Hus1+/neoAtm-/- (n=9) and Hus1neo/neoAtm-/- 
(n=12) mice. The cohort treated with 5Gy included Hus1+/neoAtm+ (n=4), 
Hus1neo/neoAtm+/+ (n=6), Hus1+/neoAtm-/- (n=6) and Hus1neo/neoAtm-/- (n=4) mice. There 
were no significant differences in survival between Hus1+/neoAtm-/- and Hus1neo/neoAtm-/- 
mice after 4Gy (p=0.295) or 5Gy (p=0.366) as determined by log-rank test. 
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Figure 2.11. Rapid senescence and defective colony formation in Hus1/Atm 
double mutant MEFs. A) Primary mouse embryonic fibroblasts (MEFs) were 
isolated and maintained on a standard 3T3 culture protocol. Cumulative population 
doublings were calculate over time and plotted. B) Spontaneously immortalized 
Atm/Hus1 MEFs were plated at 5 x 102 or 3 x 103 cells per well of 6 well dishes, and 
the colony forming potential of each cell line was assessed. 
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the colony forming potential of each cell line. Colony formation was reduced in 
immortalized Hus1neo/neoAtm+/+ cells and impaired to an even greater degree in 
Hus1+/neoAtm-/- MEFs. Remarkably, Hus1neo/neoAtm-/- MEFs were completely defective 
for colony formation, under either atmospheric (Figure 1.11B) or low (data not 
shown) oxygen conditions, despite the fact that these cells showed normal 
proliferation when cultured at higher densities. Thus, simultaneous defects in Atm and 
Hus1 result in accelerated senescence and, despite being compatible with spontaneous 
immortalization, cause profound impairment of the capacity of single cells to grow 
out as colonies. 
 To further understand the cooperative relationship between HUS1 and ATM in 
DNA damage signaling, we next treated the Atm/Hus1 primary MEFs with UV or IR 
and assessed the activation of canonical ATR and ATM downstream targets. 
Untreated Hus1neo/neoAtm-/- MEFs had slightly higher basal levels of p53 and phospho-
CHK1 (Figure 2.10B), suggestive of increased spontaneous DNA damage 
accumulation. Moderate Hus1 impairment alone had no detectable effect on DNA 
damage signaling upon IR treatment, with comparable levels of CHK2 
phosphorylation and p53 accumulation occurring in Hus1+/neoAtm+/+ and 
Hus1neo/neoAtm+/+ cells. The slight accumulation of phosphorylated CHK1 following IR 
also was unchanged in Hus1neo/neoAtm+/+ cells. Lacking ATM alone, Hus1+/neoAtm-/- cells 
showed delayed induction of both CHK2 and p53 following IR and a slight increase 
in CHK1 phosphorylation. Interestingly, Hus1neo/neoAtm-/- MEFs showed the same IR-   
 
90 
 
 
 
Figure 2.12. Increased chromosomal abnormalities in Hus1/Atm double 
mutant MEFs. Metaphases from passage 1 (P1) cells lines of the following genotypes 
were utilized: Hus1+/neoAtm+/+ (n=3), Hus1neo/neoAtm+/+ (n=3), Hus1+/neoAtm-/- 
(n=4), Hus1neo/neoAtm+/+ (n=4). Chromosome preparations were stained with Giemsa 
and imaged at 160X magnification. A) Images of Hus1/Atm MEFs of the indicated 
genotypes are shown. Red arrowheads point to chromosomal breaks/gaps. The panel 
for Hus1neo/neoAtm-/- genotype exemplifies a typical metaphase with extensive 
chromosomal abnormalities. B) Quantification of the frequency of chromosomal 
abnormalities per metaphase spread in Hus1/Atm MEFs of the indicated genotypes. 
Extensive damage refers to metaphases that contained too many chromosome 
abnormalities to be counted. C) Table of occurrence of the different types of gross 
chromosomal abnormalities. The total number of breaks/gaps, fusions, radial 
chromosomes and acentric chromosomes was quantified for cells of each genotype. 
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induced DDR kinetics as Hus1+/neoAtm-/- cells, and the magnitude of the response was 
similar with the exception that CHK1 activation after IR was even greater in cells 
defective for both Atm and Hus1. In response to UV, CHK2 and CHK1 
phosphorylation as well as p53 accumulation were unaffected by Atm inactivation, 
partial Hus1 impairment, or both (Figure 2.10B). Although defects in other signaling 
events not analyzed here cannot be ruled out, these data suggest that primary 
Atm/Hus1 double mutant cells can trigger key DNA damage checkpoint signaling 
events as well as the single mutants. As a final measure of how interactions between 
Atm and Hus1 affect DNA damage responses, we compared the radiation sensitivity 
of mice with individual or combined defects in Atm and Hus1. Consistent with the 
lack of detectable synergistic effects on IR-induced checkpoint signaling in MEFs, 
Atm/Hus1 double mutant mice showed an equivalent sensitivity to whole body IR 
exposure as Atm single mutant mice, which are hypersensitive to IR (Figure 2.10C). 
Thus, the defective DSB response in Atm-deficient mice is not substantially worsened 
by additional partial Hus1 impairment.  
2.5 Discussion 
 The ATM and ATR DNA damage checkpoint pathways initially were viewed as 
separable, parallel signaling cascades that respond to distinct DNA lesions. However, 
recent biochemical evidence indicating significant crosstalk between the two pathways 
has led to the concept of a broad, integrated DDR network (Matsuoka, Ballif et al. 
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2007). Nevertheless, the genetic relationship between these pathways in vertebrates 
has been difficult to investigate due to the lethality associated with complete 
inactivation of ATR pathway components. Here we used a system for partial Hus1 
inactivation to show for the first time that ATM and HUS1 cooperate in genome 
maintenance in vivo. Whereas mice defective for either Atm or Hus1 alone are viable, 
simultaneous dysfunction of both genes resulted in synthetic lethality. The ability to 
finely tune Hus1 expression levels further revealed tissue-specific phenotypes, such as 
craniofacial and limb defects, associated with moderate Hus1 impairment in an Atm-
deficient background. This was unexpected, as the two main mammalian DDR 
pathways are often considered ubiquitously important, and suggests that there is 
significant tissue-specific variation in the level of endogenous DNA damage and/or 
the activity of additional pathways that respond to DNA lesions. Mapping out these 
specificities will be critical for understanding the etiology of many inborn diseases as 
well as the nature of organismal responses to chemotherapeutics and other genotoxic 
agents.  
 The most striking phenotype in Hus1neo/neoAtm-/- mice was their significantly 
reduced overall size, which was apparent prior to birth. In mice and humans there are 
several reports of dwarfism associated with DDR defects, but the underlying 
mechanisms are still poorly understood in many cases. Most theories for how DDR 
dysfunction causes dwarfism center on either cell-autonomous defects or systemic 
growth axis perturbations. In particular, impairment of nucleotide excision repair in 
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mouse models of Cockayne syndrome results in dwarfism that is associated with 
suppression of the growth hormone/insulin-like growth factor (GH/IGF1) axis in 
what is believed to represent a homeostatic feedback response to GIN (Niedernhofer 
2008). Likewise, SIRT6 deficiency in mice results in genomic instability, reduced 
Gh/Igf1 expression, and dwarfism (Mostoslavsky, Chua et al. 2006). Conversely, other 
mouse models in which inactivation of genome maintenance mechanisms leads to 
dwarfism maintain an intact somatotroph axis. For instance, Atm-null mice are slightly 
smaller than their littermates (Barlow, Hirotsune et al. 1996; Elson, Wang et al. 1996; 
Xu, Ashley et al. 1996) but show no differences in the circulating levels of GH or free 
IGF1 (Schubert, Schmitz et al. 2009). Similarly, mice lacking KU80, a subunit of the 
DNA-PK complex, are smaller than their littermates but have an intact somatotroph 
axis (Nussenzweig, Chen et al. 1996; van de Ven, Andressoo et al. 2006). 
 Notably, proportional dwarfism is a characteristic of humans with Seckel 
Syndrome. Clinical reports indicate that the GH/IGF1 axis is normal in Seckel 
patients, although an Atr-Seckel mouse model shows reduced Igf1 and Ghr expression 
(Kjaer, Hansen et al. 2001; Murga, Bunting et al. 2009). Interestingly, Seckel Syndrome 
also can be caused by mutations in genes encoding centrosomal proteins, including 
PCNT, CEP152 and CENPJ (Griffith, Walker et al. 2008; Rauch, Thiel et al. 2008; Al-
Dosari, Shaheen et al. 2010; Kalay, Yigit et al. 2011). In these cases, defective cell 
division has been hypothesized to drive the cell loss that underlies the reduced body 
size. The apparently normal GH/IGF1 axis in Atm/Hus1 mice suggests that a cell 
 
95 
autonomous defect also might be responsible for the proportional dwarfism reported 
here and raises the possibility that DNA damage accumulation upon combined Atm 
and Hus1 impairment leads to small size through defective expansion of key cell 
populations, either throughout the body or in specific compartments that impact body 
size, such as stem cell pools or developing bone growth plates (Klingseisen and 
Jackson 2011; Lui and Baron 2011). 
 In addition to their small size, Atm/Hus1 double mutant animals showed 
skeletal abnormalities that included incomplete ossification and aberrant architecture 
of the skull, as well as significant shortening of the mesophalanx of the fifth digit 
(brachymesophalangy V) in both forelimbs and hindlimbs.  Craniofacial defects are 
common in patients suffering from GIN-related disorders, including Seckel Syndrome 
(Goodship, Gill et al. 2000), Nijmegen Breakage Syndrome (due to NBS1 mutations) 
(Digweed and Sperling 2004) and Williams-Beuren Syndrome (caused by a micro-
deletion at 7q11.23 that includes RFC2) (Osborne 1999). Digit abnormalities, 
including brachymesophalangy and clinodactyly, are frequently observed in patients 
with Seckel Syndrome as well as another GIN disorder, Fanconi Anemia (De 
Kerviler, Guermazi et al. 2000). In addition to their association with hereditary 
disease, craniofacial defects and brachymesophalangy V also are present following 
fetal exposure to teratogens such as alcohol (Manning and Eugene Hoyme 2007) and 
may be hallmarks of excessive DNA damage during development (Holmes, Kleiner et 
al. 1987) (Table 4.1). Why GIN is frequently associated with these particular 
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developmental phenotypes is largely unknown, but may reflect a heightened stress 
sensitivity in certain cell types.  Such a mechanism has been identified in Treacher 
Collins Syndrome, in which the occurrence of craniofacial abnormalities has been 
attributed to a lower threshold of neural crest cells for stress induced p53-dependent 
apoptosis (Jones, Lynn et al. 2008). In Atm/Hus1 mice, cell death triggered by 
increased genomic instability could potentially impact crest-derived cells required for 
suture maintenance, possibly explaining the retarded dorsal expansion of these 
roofing bones. The lateral fenestrations in Atm/Hus1 skull bones beginning at the 
initial stages of bone formation suggest that early ossification is disrupted, but do not 
provide clues as to why these specific sites are affected. The mouse model described 
here will be a powerful tool for understanding cell-type specific responses to GIN and 
their roles in the developmental defects observed in patients with instability 
syndromes. 
 Increased GIN in Atm/Hus1 double mutant mice was readily apparent during 
embryogenesis as well as in a tissue specific pattern in adults, as evidenced by 
increased MN formation in hematopoietic cells without detectable upregulation of 
DNA damage responsive genes in liver. HUS1 loss causes chromosomal instability 
specifically during S-phase (Zhu and Weiss 2007), and the observations reported here 
are consistent with a model in which the phenotypes associated with combined Atm 
and Hus1 defects are due primarily to the failure of actively dividing cells to deal with 
replication stress. Surprisingly, the elevated GIN in Atm/Hus1 mice did not 
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significantly change the onset or histological characteristics of thymic lymphomas 
relative to those arising in mice lacking Atm alone. It may be that the rapid onset of 
lymphomas in Atm-null mice obscures effects associated with partial Hus1 
impairment. Alternatively, a greater level of genomic instability in Atm/Hus1 double 
mutant mice may have opposing consequences that neutralize each other, both fueling 
the accumulation of cancer promoting mutations and interfering with the ability of 
cancer cells to withstand stresses associated malignant transformation. Finally, the 
absence of a difference in tumor-free survival may reflect a limited requirement for 
Hus1 in this compartment. Previous studies have shown that thymocytes rely more on 
ATM and DNA-PK than ATR (Callen, Jankovic et al. 2009), and our own work 
suggests that lymphocytes can tolerate Hus1 loss better than other cell types (Levitt, 
Liu et al. 2005; Francia, Weiss et al. 2006; Yazinski, Westcott et al. 2009). 
 Unexpectedly, although we deregulated the two primary DNA damage 
checkpoint pathways in the Atm/Hus1 mouse model and observed clear phenotypic 
consequences, we detected only limited alterations in canonical ATM/ATR-mediated 
DNA damage signaling events as compared to those in Atm mutants alone. Indeed, 
for some of the factors analyzed, DNA damage signaling was increased in Atm/Hus1 
embryos and MEFs. There are several possible explanations for these observations. 
First, upon deregulation of the ATM and ATR pathways, an overlapping DDR kinase 
could become activated. Among the several possible factors that could serve such a 
role, the best candidate may be the PIKK DNA-PK, which is known to cooperate 
 
98 
with ATM and ATR in H2AX phosphorylation and is capable of phosphorylating an 
array of DDR proteins in vitro, including CHK2 and p53 (Meek, Dang et al. 2008). 
However, CHK1 activation was readily apparent in Atm/Hus1 double mutants and 
there is limited evidence that DNA-PK phosphorylates CHK1 (Jazayeri, Falck et al. 
2006). Alternatively, ATR could mediate the checkpoint signaling either in a 911 
independent manner (Navadgi-Patil and Burgers 2009) or via residual HUS1 
expression from the hypomorphic Hus1 allele. Although Atm/Hus1 defective cells can 
sense and mount signaling responses to DNA damage, this response clearly is 
ineffective, resulting in GIN followed by massive apoptosis and embryonic lethality. 
The observed accumulation of genome damage could be due to a repair defect, an 
elevated damage load that overwhelms the repair machinery, or both. Hus1 
impairment did not further worsen the radiation sensitivity of Atm-null mice, 
indicating that the synthetic phenotypes in Hus1/Atm double mutant mice are unlikely 
to originate from more severe DSB response defects relative to those in Atm single 
mutants. Given that the 911 complex has been directly implicated in several DNA 
repair processes, including base excision repair and translesion synthesis, we favor the 
model that defective DNA repair following HUS1 deregulation leads to an increased 
number of DNA lesions that are normally resolved efficiently in an ATM-dependent 
manner, resulting in the observed synthetic lethality when both pathways are defective 
simultaneously (Figure 2.12).  
 The strong genetic interaction between Atm and Hus1 in mice also has 
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implications for human disease. First, the synergistic increases in genome damage and 
apoptosis observed here following combined Atm and Hus1 impairment suggest that 
therapeutic targeting of HUS1 or the broader ATR pathway may be effective for 
some malignancies that arise due to ATM pathway mutations, which may be as many 
as 30% of all cancers (Shiloh 2003; Reaper, Griffiths et al. 2011). However, the 
efficacy of such a strategy may depend on the cell of origin or other factors like the 
particular initiating oncogenic events in the tumor, as the impact of simultaneous Atm 
and Hus1 defects varied between tissues. Another implication of this work relates to 
the basis for variant forms of A-T, like A-TFresno, which is associated with ATM 
mutations but combines typical A-T phenotypes with microcephaly and mental 
retardation (Gilad, Chessa et al. 1998). This variation has been attributed to genetic 
modifiers outside of ATM. The findings presented here suggest that polymorphisms 
in HUS1 or other ATR pathway genes could significantly impact the onset and 
severity of A-T phenotypes. 
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 CHAPTER 3 
 
GENOTOXIN-SPECIFIC IN VIVO REQUIREMENT FOR HUS1 AND 
ATM FOLLOWING DNA-DAMAGE 
3.1 Abstract 
Cells are under constant attack from DNA-damaging agents from both 
endogenous and exogenous sources and protect genomic integrity through DNA-
damage response (DDR) pathways that recognize lesions and promote repair, 
senescence or apoptosis. Central to the DDR are the ATM and ATR kinases. ATM 
responds mainly to double strand DNA breaks whereas ATR orchestrates the cellular 
response to replication stress.  Because complete ATR pathway inactivation causes 
embryonic lethality, we created an allelic series in which the expression of Hus1, a 
member of the 911 complex that is required for efficient ATR signaling, is 
incrementally reduced by combining the wild-type allele (Hus1+) with either 
hypomorphic (Hus1neo) or null (Hus1Δ1n) alleles. Hus1neo/∆1n mice, which have the lowest 
levels of Hus1 in this series, are born at expected frequency and appear grossly normal 
but show increased genomic instability and no increased cancer predisposition.  Since 
little is known about the in vivo roles of the ATR pathway following genotoxic stress, 
we defined the tissue- and cell type-specific actions of the Hus1-mediated DDR.  
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Hus1neo/∆1n mice showed significant hypersensitivity to agents that cause replication 
stress, including MMC and HU, but not to IR, which causes DSBs.  Analysis of cell 
proliferation and apoptosis in IR sensitive tissues such as the small intestine and skin 
showed that partial Hus1 inactivation had no detectable effect on radiation induced 
cell cycle arrest or apoptosis.  Together our data shows that in response to genotoxic 
stress there is a clear separation of the two pathways supporting the hypothesis that 
the overlap between the two pathways occurs because DNA lesions conversion.  Our 
current research focuses on understanding the cellular and molecular mechanisms that 
are the basis of this sensitivities and the relationship between the ATM and ATR 
pathways in responding to genotoxic agents.  A better understanding of how 
checkpoint signaling impacts the responsiveness of normal tissues as well as tumors to 
genotoxins will give us insights into how inhibitors of checkpoint signaling pathways 
may interact with traditional cancer therapies.  
3.2 Introduction 
DNA stands at the core of life as we know it.  In order to perform its function 
each cell of our organism relies on DNA for the execution of vital functions such as 
transcription or replication.  Thus, to protect its integrity and the integrity of its 
future progeny, cells have to deal with a plethora of agents that damage the DNA.  
DNA damage originates from both endogenous and exogenous sources and can 
cause an array of lesions spanning from a base mismatch to the most toxic DSBs 
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(Jackson and Bartek 2009; Abraham and Halazonetis 2012).  To deal with these 
threats cells have evolutionary developed a series of cell cycle checkpoints that allow 
for DDR.  Central to the DDR lays a series of signal transduction pathways that 
sense the damage and transduce the signal to effector molecules that execute the 
appropriate response, being it repair or apoptosis.  The main pathways involved in 
cellular protection from DNA damage are the ATM and ATR pathways (Cimprich 
and Cortez 2008; McKinnon 2012).  ATM and ATR are large protein kinases of the 
phosphatidylinositol 3-kinase-related kinases (PIKKs) family that initiate each of 
these pathways.  ATM responds mainly to DSBs while ATR responds to the 
presence of RPA coated single stranded DNA (RPA-ssDNA) as a result of 
replication stress.  
ATM is the principal responder to DSBs and once activated phosphorylates, 
through others, the downstream effectors CHK2 and p53. These steps activate the 
DDR checkpoint and promote DNA repair.  The important role of the ATM kinase 
is underlined by the phenotypes associated with loss of function mutations in this 
gene.  In humans these mutations are associated with Ataxia-Telangiectasia (AT; 
OMIM 208900) a genomic instability syndrome characterized by extreme sensitive to 
IR, ataxia, telangiectasias, immune deficiency, sterility and an increased risk of 
lymphoma formation (McKinnon and Caldecott 2007; McKinnon 2012).  An Atm 
mouse model for A-T has been engineered, that recapitulates many of the human 
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phenotypes (Barlow, Hirotsune et al. 1996; Elson, Wang et al. 1996; Xu, Ashley et al. 
1996).  Atm-/- mice have been subjected to extensive genotoxin analyses that 
strengthened the concept that ATM is the main responder to IR but not replication 
stress.  At sub-lethal doses of IR, Atm-/- mice are immediately affected and die 
rapidly due to gastrointestinal toxicity (Barlow, Hirotsune et al. 1996).  In Atm-/- mice 
the CNS is resistant to apoptosis after 14 Gy ionizing radiation including in the 
cerebellum, which is markedly affected in AT.  In wild-type, but not Atm−/− mice, 
p53 was activated, suggesting that Atm-dependent apoptosis in the CNS is mediated 
by p53 (Herzog, Chong et al. 1998). 
The ATR pathway responds to lesions caused by genotoxins like UV-light, 
HU or MMC, which create a physical barrier for the replication fork progression.  
When the replication machinery encounters such a lesion and the DNA-polymerases 
are unable to bypass it, the MCM helicases associated with the fork continue to 
unwind the DNA creating long stretches of ssDNA.  This ssDNA, immediately 
protected by RPA, represents the major signal for recruitment of ATR, through its 
partner ATRIP and the RAD9-RAD1-HUS1 clamp (9-1-1).  The 9-1-1 complex 
recruits to the lesion site TopBP1 and RHINO which then activate ATR kinase 
activity (Delacroix, Wagner et al. 2007; Cotta-Ramusino, McDonald et al. 2011).  
Upon activation, ATR phosphorylates the downstream effector CHK1 to promote 
cell cycle arrest and allows for repair. 
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In humans rare syndromes are associated with ATR deficiency (O'Driscoll 
2008).  One such disease is Seckel Syndrome (SKL1; OMIM) caused by a 
hypomorphic loss of function mutation in ATR.  Seckel patients present with 
dwarfism, microcephaly and mental retardation, but no cancer predisposition 
(Goodship, Gill et al. 2000; O'Driscoll, Ruiz-Perez et al. 2003).  In order to better 
study the importance of the ATR pathway for human physiology mice models for 
deficiency in the ATR pathway have been created.  Knocking out any member of the 
ATR pathway resulted in severe embryonic lethality, consistent with the notion that 
ATR is a critical factor for replication stress (O'Driscoll 2009).  Thus hypomorphic 
alleles were created to deregulate the ATR pathway.  A transgenic mouse model 
bearing the humanized ATR allele (AtrS) exhibits partial ATR expression, with AtrS/S 
homozygous mice showing severe phenotypes including dwarfism and craniofacial 
defects.  These mice succumb rapidly to the severity of their disease.  Thus, analysis 
of the in vivo response to genotoxins is impossible (Murga, Bunting et al. 2009).   
A different tactic was employed by our group that used HUS1 to deregulate 
the ATR pathway.  A Hus1 knockout allele where Hus1 exon 1 was removed 
(Hus1Δ1n) was combined with either the wild type allele (Hus1+) or a hypomorphic 
allele (Hus1neo) to create a Hus1 allelic series where Hus1 expression was 
incrementally decreassed (Hus1+/+ > Hus1+/neo > Hus1+/Δ1n > Hus1neo/neo > Hus1neo/Δ1n).  
While Hus1+/neo and Hus1+/Δ1n mice are indistinguishable from Hus1+/+ mice, and in 
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our studies were used as wild type controls, Hus1neo/Δ1n mice show the lowest Hus1 
expression in the series, are viable and born at expected frequencies, show a grossly 
normal phenotype, no increase in cancer predisposition but an increase in 
micronucleus formation in the peripheral blood, indicating that the reduced Hus1 
expression is insufficient for proper genome maintenance.  Hus1neo/neo mice with 
intermediate Hus1 expression show medium GIN phenotypes (Levitt, Liu et al. 2005; 
Levitt, Zhu et al. 2007).  
The two DDR pathways have been thought to act as parallel pathways 
(Cimprich and Cortez 2008; Shiotani and Zou 2009).  and any cross-talk seen in 
checkpoint activation and DNA repair has been attributed to DNA lesion 
conversion: unrepaired stalled replication forks can eventually collapse in DSBs while 
in the repair of DSBs, ssDNA intermediates are formed.  This concept has been 
recently challenged by cellular and biochemical assays where the two pathways have 
been shown to act as an integrated mechanism.  ATM and ATR have been shown to 
have more than 700, highly interconnected, phosphorylation substrates (Matsuoka, 
Ballif et al. 2007).  Moreover, cellular analysis of the ATR pathway deficiency has 
shown that ATR pathway defective cells are sensitive to IR as well as replication 
stress reagents.  Concomitant inhibition of both ATM and ATR pathways resulted in 
synthetic lethality (Weiss, Matsuoka et al. 2002; Weiss, Leder et al. 2003; Murga, 
Bunting et al. 2009).  Due to a lack of available genetic tools, the analysis of the 
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relationship between these two pathways in live organisms has been difficult due to 
the lethality associated with the knockout of any member of the ATR pathway.  By 
combining the Hus1 allelic series on Atm-/- background we showed that in vivo, like in 
vitro Hus1/Atm double mutant mice showed a synthetic lethal phenotype (Chapter 2).  
Contrary to our expectation, the synthetic lethality associated with Hus1/Atm 
impairment did not further accentuate the sensitivity to DSB formation, since 
Hus1/Atm double mutant mice were no more sensitive to IR as Atm single mutants.  
This suggests that all the phenotypes associated with Hus1/Atm deficiency are due to 
a replication stress problem (Balmus, Zhu et al. 2012).  
While the role of the ATM pathway in tumor progression is well understood, 
the importance of the ATR pathway remained elusive and contradictory, with some 
studies proposing that the ATR pathway is critical for tumor suppression while 
others suggested a role in tumor growth (Smith, Tho et al. 2010).  Whereas tumor 
susceptible mice showed an increased in tumor incidence when heterozygous 
mutations in members of the ATR pathway were included, humans suffering from 
ATR deficient syndromes are not prone to tumor development (Goodship, Gill et al. 
2000).  Moreover, data from human patients showed that members of the ATR 
pathway were upregulated in tumors (Maniwa et al., 2005; Zhu et al., 2008).  
Increased expression of DDR proteins including HUS1 were also detected in 
mammary tumors in mice (Zhang et al., 2008).  These observations suggest that the 
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ATR pathway is critical for tumor development.  Indeed, in mice, loss of HUS1 or 
ATR synergize with p53 loss to promote cell death and not tumorigenesis 
(Ruzankina et al., 2009; Yazinski et al., 2009).  Furthermore ATR pathway inhibitors 
induce increased sensitivity to chemotherapeutics in several cancer cell lines (Ma, Cai 
et al. 2012; Origanti, Cai et al. 2012).  These inhibitors are believed to represent an 
Achilles’ heel of cancer (Bartek, Mistrik et al. 2012).  Less is known though about the 
effect of ATR pathway inhibition in a normal organism. 
Here we used the Hus1 deficient mice to test the in vivo requirement for the 
ATR pathway under physiological and genotoxin treatment conditions.  We show 
that in response to genotoxin stress in vivo the ATM and ATR pathways act as 
separate parallel pathways.  Hus1neo/Δ1 mice are no more sensitive to the DSB 
inducing clastogen IR than wild type controls but are hypersensitive to the 
replication stress inducing reagents MMC and HU.  We show that the intercross 
between the two pathways is most likely due to an interconversion of the DNA 
lesions and that the fine tuning of ATR pathway inhibition will be critical for 
successful combined cancer therapies. 
3.3 Materials and methods  
Animals. All animals used in this study were handled in accordance with federal and 
institutional guidelines, under a protocol approved by the Cornell University 
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Institutional Animal Care and Use Committee (IACUC). Hus1neo and Hus1Δ1n mice 
were maintained on the 129S6 background.  Atm knockout mice were maintained on 
the FVB background. These strains were interbred to create Atm/Hus1 double mutant 
mice. Mice were genotyped by PCR analysis of genomic DNA isolated from tail snip 
biopsies as previously described.  
Hydroxyurea treatment. For analysis of hydroxyurea (HU) sensitivity during embryonic 
development timed matings using Hus1 allelic series mice were performed. Noon of 
the day of vaginal plug detection was defined as embryonic day E0.5. Pregnant 
females at E8 were injected via intraperitoneal delivery (IP) 400 mg/kg body weigh 
HU and embryos were dissected at 12 hours later for analysis. Embryos were 
genotyped by PCR analysis of genomic DNA isolated from by laser microdissection 
of embryonic tissues using a Leica LMD6000 microscope.  
Ionizing radiation and mytomycin C treatment. For analysis of survival upon ionizing 
radiation, mice were subjected to 9Gy or 15Gy doses of γ-irradiation using a Mark I 
Model 68 sealed 137Cs source gamma irradiator (JL Shepherd & Associates), injected 
with a single IP dose of 8mg/kg or 4mg/kg body weigh mitomycin C (MMC - Sigma). 
Subsequently mice were monitored by daily weighing for up to 30 days or until 
reaching humane endpoint criteria based on the clinical disease signs.  Kaplan-Meier 
survival analysis was performed using IBM SPSS software. 
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Histology.  At the indicated time points after the specified genotoxin treatment, all 
major organs were isolated following euthanasia and then fixed in 10% formalin 
overnight.  The second day the fixed organs were transferred to 70% ethanol, were 
placed in cassettes, embedded in paraffin and serial 5 μm sections were collected on 
Superfrost Plus slides (Fisher) using a Leica microdissection system (LMD7000).  
Histological sections of paraffin-embedded tissues were stained with hematoxylin and 
eosin using a standard protocol.  Upon staining specimens were subjected to 
pathological assessment.   
 
Immunohistochemistry staining.  To quantify cell proliferation bromodeoxyuridine (5-
bromo-2'-deoxyuridine, BrdU), a synthetic thymidine analog was used.  Two hours 
prior to euthanasia mice were injected i.p. with an 8mg/kg dose of BrdU using a 
50µg/µl stock solution.  To quantify the proliferation potential the slides were 
analyzed using the BrdU kit (Invitrogen) according with the manufacturer’s directions.  
Apoptosis quantitation was done using the Apoptag (Millipore) TUNEL detection 
system according to the manufacturer's instructions.  In the case of the small intestine, 
individual, morphological intact crypts were identified and more than five crypts per 
mouse were counted.  For the skin, intact hair follicles were used for quantitation by 
counting the distribution of DAB positive cells.  Histology images were obtained 
using an Aperio Scanscope (Aperio Technologies, USA).  Statistical analysis was 
performed using SPSS’s (IBM) Mixed Model Analysis. 
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Effect of genotoxin treatment on micronucleus formation.  Analysis of micronucleus (MN) 
formation in peripheral blood cells was performed as previously described (Shima, 
Hartford et al. 2003; Levitt, Zhu et al. 2007).  Briefly, peripheral blood was collected 
from the mandibular vein at 0, 24, 48 and 76 hours post 07Gy IR, fixed in methanol, 
and incubated in bicarbonate buffer containing RNase A and anti-CD71: FITC 
antibody (Biodesign International).  After washing and staining with propidium iodide, 
the cells were analyzed on a FACSCalibur flow cytometer (Becton-Dickinson, San 
Jose, CA). 
 
3.4 RESULTS 
3.4.1 Hus1 impairment does not alter survival upon ionizing radiation 
treatment. 
Due to their deficiency in DDR factors many cancer types are selectively 
sensitive to radiation based therapy (Mellor and Callaghan 2008).  Targeting cancer 
with clastogens like ionizing radiation represents one of the most effective forms of 
treatment being used for many malignant tumors at various developmental stages 
(Gudkov and Komarova 2003).   
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Although a main DDR response pathway, due to the lethality associated with 
ATR pathway deficiency, the role of ATR pathway in the response to DSB formation 
in vivo remained unexplored.  Because in vitro experimental data hinted for a 
requirement for this pathway in response to DSBs, with Hus1 null cells being 
significantly more sensitive to IR than their wild type controls (Weiss, Matsuoka et al. 
2002), we hypothesized that Hus1 defective animals like the cells would show a 
specific higher sensitivity to IR. 
To test this hypothesis we treated Hus1neo/Δ1n mice and control littermates with 
9Gy and 15Gy IR doses respectively.  Upon treatment, Kaplan Meyer analysis showed 
that independent of the dose used, Hus1neo/Δ1n mice showed no significant difference in 
survival when compared to Hus1 controls, while the Atm-/- control group was 
hypersensitive (Figure 3.1).  As previously reported (Bunz, Hwang et al. 1999; Takai, 
Naka et al. 2002), hematoxilin and eosin (HE) histopathological examination of 
tissues from the wild type treated groups showed, acute modifications in the thymus, 
spleen, bone marrow, spermatogonia, epithelia of the gut and hair follicles.  In 
comparison to the Hus1+ control group, tissues from Hus1neo/Δ1n mice showed no 
specific signatures (Table 3.1), suggesting that similar to the response at organismal 
level, at cellular level, there is no specific requirement for Hus1 in response to IR.  
These observations indicate that in vivo the ATR pathway is not required for the 
organismal response to IR induced stress..  
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Figure 3.1. Hus1 hypomorphic mice show no differential sensitivity to IR.  Mice 
of the indicated genotypes were exposed to 6Gy, 9Gy or 15Gy respectively of IR 
from a sealed source cesium irradiator. Animals were monitored for survival and a 
chi-square statistical analysis was performed. Control Hus1+ genotypes include 
Hus1+/+, Hus1+/neo, and Hus1+/Δ1.  Kaplan-Meyer survival analysis shows that while 
Atm-/- mice are hypersensitive to IR, Hus1neo/Δ1 mice shows no significant 
hypersensitivity to IR at both 9Gy (B) and 15Gy (C) doses when compared to the 
Hus1+ littermate controls.  
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3.4.2 Similar IR induced responses in the tissues of the Hus1 mutant mice. 
Most of the phenotypes associated with the clinical signs of radiation 
intoxication, for either the hematopoietic or gastrointestinal lethal syndromes, are 
caused by an increased cell death in the respective compartments associated with 
changes in cell proliferation (Norimura, Nomoto et al. 1996).  Because some of the 
Hus1 specific changes might have been hidden by the accumulating secondary effects 
caused by radiation exposure, analysis of cell proliferation and apoptosis was 
performed at 8 hours and 96 hours post 15Gy IR, before the emergence of severe 
clinical signs.  While at 8 hours post IR little changes were noted in the tissues 
examined, histopathological examination of tissues harvested 96 hours post IR 
showed a primary response in the skin and the epithelia of the gut represented by a 
cell loss in the hair follicle and hyperplasia in the intestinal crypt epithelia (Figure 3.2).   
To specifically examine cellular proliferation and apoptosis in the small 
intestine and skin of our mice apoptosis was measured using TUNEL while cell 
proliferation was measured using a BrdU incorporation assay as described in Material 
and Methods.  The examination of the apoptosis in the hair follicle of the 15 Gy 
treated mice revealed a mild increase in cell death at the level of the hair follicle.  
These differences were present and similar at both 8 and 96 hours post 15 Gy IR and 
were independent of the Hus1 status (Figure 3.3A).  Following the exposure to a 
DNA damaging agent the proliferation at the level of the hair follicle arrested 
progressively at 8 and 96 hours post treatment.  These changes were again 
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independent of the Hus1 status (Figure 3.3B).  Consistent with the survival data, 
deregulation of the ATR pathway in the Hus1 mutant mice has no significant effect on 
the cell proliferation and apoptosis of the hair follicle cells, suggesting that at this level 
the ATR pathway is not required for the response to IR. 
To further investigate the Hus1 requirement following IR, we next evaluated 
the response to IR in a highly proliferative tissue, the small intestine.  The cells in the 
small intestinal crypt proliferate continuously with all the cells being completely 
renewed in 24 hours (Crosnier, Stamataki et al. 2006).  Analysis of the cell survival 
status in the small intestine revealed that at 8 hours post 15-Gy IR a significant 
proportion of the cells from the small intestinal crypt underwent cell death while at 96 
hours post-treatment the small intestinal crypts had numbers of apoptotic cells similar 
to the untreated groups, implying that they have a checkpoint defect.  8 hours post-
treatment, the Hus1neo/Δ1n mice showed an increased apoptosis trend compared to 
Hus1+ controls.  96 hours post-treatment the difference was indistinguishable (Figure 
3.4A).  Proliferation analysis showed that in the untreated group the Hus1neo/Δ1n show a 
significant reduction in the proliferative capacity of the small intestinal crypts 
compared to the Hus1+ controls.  8 hours post 15 Gy treatment the Hus1neo/Δ1n shows 
almost no change in the proliferation potential compared to representative untreated 
mice.  The Hus1+ control group showed a significant drop in proliferation.  96 hours   
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Figure 3.2. Tissue morphology in mice with partial Hus1 impairment following 
15Gy ionizing radiation.  Following euthanasia, isolated tissues were fixed in 10% 
formalin.  Histological sections of paraffin-embedded tissues were stained with 
hematoxylin and eosin (HE) and subjected to pathological assessment.  (A) 
Representative images depicting tissue morphology in the skin from Hus1neo/Δ1 mice 
compared to littermate controls upon 15 Gy IR.  The hair follicles are grossly normal 
8hrs post IR but loss of cellularity is observed at 96hrs post treatment.  No difference 
in cellularity of the hair follicles was observed between the two genotypic groups  (B) 
Representative images depicting tissue morphology in the small intestine of Hus1neo/Δ1 
mice as compared to littermate controls upon 15 Gy IR.  The small intestine crypts 
are grossly normal 8hrs post IR but enlarged 96hrs post treatment.  No difference in 
cellularity in the small intestine was observed between the two genotypic groups post 
15Gy IR.  Size bar corresponds to 50 microns.  Control Hus1+ genotypes include 
Hus1+/+, Hus1+/neo, and Hus1+/Δ1. 
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Figure 3.3.  Analysis of cell proliferation and apoptosis in the skin from 
Hus1neo/Δ1 as compared to Hus1+ mice following 15Gy ionizing radiation.  
Immunohistochemical staining of TUNEL positive cells and BrdU positive cells in 
paraffin embedded skin from experimental mice.  (A) Representative images depicting 
TUNEL positive cells, indicative of apoptosis, in the skin from Hus1neo/Δ1 mice as 
compared to littermate controls after no treatment or the indicated time points after 
15Gy IR.  (B) Quantification of TUNEL positive cells in the skin at 0, 8, and 96 hrs 
post 15Gy.  Significant increased levels of apoptosis were observed 8 hrs post 15Gy 
IR (p<0.05; Student’s t test) at similar levels in both genotypic groups.  (C) 
Representative images depicting BrdU positive cells, indicative of proliferation, in the 
skin of Hus1neo/Δ1 mice as compared to littermate controls after no treatment or the 
indicated time points after 15Gy IR.  (D) Quantification of BrdU positive cells in the 
skin at 0, 8, and 96 hrs post 15Gy.  Significantly decreased levels of proliferation were 
observed at 8 hrs (p<0.05; Student’s t test) and 96 hrs (p<0.01; Student’s t test) post 
15Gy IR when compared to the untreated groups or when the 8 hrs and 96 hrs time 
point were compared (p<0.05; Student’s t test).  No significant difference between the 
Hus1neo/Δ1 mice and littermate controls was noted at any time point.  Quantification 
was done using  Size bar corresponds to 50 microns.  Control Hus1+ genotypes 
include Hus1+/+, Hus1+/neo, and Hus1+/Δ1.  n≥3 mice for each genotype and time point 
were used for quantitation; n≥3 fields of view per mouse were counted. Error bars 
represent ± standard deviation.
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Figure 3.4. Analysis of cell proliferation and apoptosis in the small intestine 
from Hus1neo/Δ1 as compared to Hus1+ mice following 15Gy ionizing radiation.  
Immunohistochemical staining of TUNEL positive cells and BrdU positive cells in 
paraffin embedded small intestine sections.  (A) Representative images depicting 
TUNEL positive cells, indicative of apoptosis, in the small intestinal crypts from 
Hus1neo/Δ1 mice compared to littermate controls after no treatment or the indicated 
time points after 15Gy IR.  (B) Quantification of TUNEL positive cells in the small 
intestinal crypts at 0, 8, and 96 hrs post 15Gy.  8 hours post 15Gy IR both genotypic 
groups showed significant increased levels of apoptosis when compared to the 
untreated group (p<0.001; Student’s t test). No significant difference between the 
Hus1neo/Δ1 mice and littermate controls was noted.  At 96 hrs the crypts showed severe 
morphology changes, but apoptosis levels returned to the untreated level.  (C) 
Representative images depicting BrdU positive cells, indicative of proliferation, in the 
small intestinal crypts from Hus1neo/Δ1 mice as compared to littermate controls after no 
treatment or the indicated time points after 15Gy IR.  (D) Quantification of BrdU 
positive cells in the small intestinal crypts at 0, 8, and 96 hrs post 15Gy.  Significant 
decreased levels of proliferation were observed in the untreated group (p=0.03; 
Student’s t test).  At 8 hrs post 15Gy IR, proliferation was significantly reduced in 
both groups (p<0.05; Student’s t test).  No significant difference between the 
Hus1neo/Δ1 mice and littermate controls was noted.  At 96 hrs, significant increased 
proliferation was observed at similar levels in both groups (p<0.05; Student’s t test).  
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Size bar corresponds to 50 microns.  Control Hus1+ genotypes include Hus1+/+, 
Hus1+/neo, and Hus1+/Δ1.  n≥3 mice for each genotype and time point were used for 
quantitation.  Quantitation was done in intact intestinal crypts and n≥5 intestinal 
crypts per mouse were counted. Error bars represent ±standard deviation. 
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Table 3.1 Major pathologic findings in Hus1neo/Δ1 mice and Hus1+ littermate controls 
after IR treatmenta. 
Dose Genotype Major pathologic findings 
9Gy 
Hus1+ 
Splenic white pulp depletion, increased red pulp 
macrophages, interstitial hemorrhage in testis, increased 
nuclear density in liver, mild neutrophilic colitis 
Hus1neo/Δ1 
Congested splenic red pulp, hemosiderin, EMH; colonic 
hyperplasia, rare neutrophils in the small intestine; moderate 
neutrophilic colitis 
15Gy 
Hus1+ Severe necrotizing gastritis with hyperplasia, mild colitis 
with necrosis and hyperplasia, middle tubular ectasia 
Hus1neo/Δ1 Severe gastric necrosis, inflammation and regeneration, SI 
contains mild hyperplasia and individual cell necrosis 
 
aSamples were fixed in 10% formalin and processed for histology. Hematoxilin and 
eosin stained slides were used for assessment. 
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post 15 Gy IR the proliferation of the small intestinal crypt cells almost doubled when 
compared to the untreated groups, with Hus1neo/Δ1n mice showing an even higher 
proliferation (Figure 3.4B).  These data show that differences in cell proliferation and 
apoptosis seen upon IR treatment in the highly replicating small intestinal crypts are 
not significantly affected by Hus1 depletion.  In both genotypic groups, we saw an 
increase in cell death at 8 hours post 15 Gy IR.  These changes were accompanied by 
proliferative compensation at 96 hours.  
 To further examine the overlap between Atm and Hus1 analysis of the cellular 
modifications in the small intestine was performed in the Hus1/Atm mice 8 hours 
post 4Gy IR.  Preliminary data showed no significant histopathologic modifications in 
the Hus1/Atm mutant mice compared to the littermate representative controls (Figure 
3.5).  The analysis of cell proliferation and apoptosis using the BrdU and TUNEL 
assays showed that while increases in apoptosis and reduced proliferation were 
observed no differences were detected between the Hus1/Atm double mutant mice 
compared to control mice (Figure 3.6 A-B; C-D).  
 We next wanted to assess the in vivo levels of genomic instability in the 
Hus1/Atm double mutant mice using micronucleus assay.  Mice of the representative 
genotypes were irradiated with a unique 0.7Gy whole body irradiation dose and blood 
was extracted before treatment (0 time point) or 24, 48 and 72 hours post treatment.  
Blood was fixed in methanol and process for MN assay as described in the Material 
and Methods.  While similar kinetics of MN formation was observed in the wild type   
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Figure 3.5. Tissue morphology in mice with Hus1/Atm impairment following 
4Gy ionizing radiation.  Following euthanasia, isolated tissues were fixed in 10% 
formalin.  Histological sections of paraffin-embedded tissues were stained with 
hematoxylin and eosin (HE) and subjected to pathological assessment.  
Representative images depicting tissue morphology in the small intestine from 
Hus1neo/neoAtm-/- mice compared to littermate controls upon 4 Gy IR.  The small 
intestinal crypts are grossly normal 8hrs post IR.  No difference in cellularity of the 
crypt was observed between the genotypic groups    
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Figure 3.6. Analysis of cell proliferation and apoptosis in the small intestine 
from Hus1/Atm double mutant mice as compared to Hus1 control group mice 
following 4Gy ionizing radiation.  Immunohistochemical staining of TUNEL 
positive cells and BrdU positive cells in paraffin embedded small intestine sections.  
(A) Representative images depicting TUNEL positive cells, indicative of apoptosis, in 
the small intestinal crypts from Hus1neo/neoAtm-/- mice compared to littermate controls 
after no treatment or the indicated time points after 4Gy IR.  (B) Quantification of 
TUNEL positive cells in the small intestinal crypts at 0 and 8.  8 hours post 4Gy IR all 
genotypic groups showed significant increased levels of apoptosis when compared to 
the untreated group (p<0.05; Student’s t test). No significant difference between the 
Hus1neo/neoAtm-/-  mice and littermate controls was noted.  (C) Representative images 
depicting BrdU positive cells, indicative of proliferation, in the small intestinal crypts 
from Hus1neo/neoAtm-/- mice as compared to littermate controls after no treatment or 
the indicated time points after 4Gy IR.  (D) Quantification of BrdU positive cells in 
the small intestinal crypts at 0 and 8 hours post 4Gy.  8 hours post 4Gy IR 
proliferation was significantly reduced in all groups (p<0.05; Student’s t test) except 
the Hus1neo/neoAtm-/- mice. Quantitation was done in intact intestinal crypts and n≥5 
intestinal crypts per mouse were counted.  Error bars represent ± standard deviation. 
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Figure 3.7. Failure to recover from IR induced genomic instability in 
Hus1neo/neoAtm-/- mice. A) Line chart shows the average percent of peripheral blood 
cells with micronuclei in mice of the indicated genotypes before treatment and 24, 48 
and 72 hours post 0.7 Gy IR treatment.  Hus1neo/neoAtm+/+ and Hus1+/neoAtm+/+ mice 
showed similar levels of GIN while Hus1+/neoAtm-/- mice start with significant increase 
in micronucleus formation (p<0.05; Student’s t test).  All of these genotypic groups 
return to basal starting levels at 72 hours post IR.  The combined effect of Hus1 
impairment in an Atm null background (Hus1neo/neoAtm-/-) resulted in higher basal levels 
of MN formation compared with all the other groups (p<0.05; Student’s t test) and 
were unable to recover to starting MN levels (p<0.05; Student’s t test).  
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group and the Hus1 and Atm single mutants at 24, 48 and 72 hours, the Hus1/Atm 
double mutant mice never recover to the initial MN levels showing that they are 
defective in the response to IR in the hematopoietic niche (Figure 3.7). 
Our data highlight a difference in the proliferative but not apoptotic potential 
of untreated intestinal crypt cells between Hus1 wild type and Hus1 mutant mice.  This 
is in line with the major role that the ATR pathway plays in highly replicative cells.  
Following IR treatment the Hus1/Atm double mutant mice fail to recover from the 
increased MN formed post IR, underlining a different response in this compartment. 
 
3.4.3 Hus1 is critical for the in vivo response to replication stress reagents 
hydroxyurea and mitomycin C. 
The ATR pathway is the main responder to replication stress induced lesions 
and as such is critical for replication progression.  Our analysis of the role of ATR 
deficient cells in response to replication stress inducing agents showed that these cells 
are highly sensitive to replication stress inducing reagents such as UV, HU or MMC 
(Yang, Yu et al. 2003). To explore the effect of ATR pathway deregulation in vivo we 
subjected Hus1 deficient mice to the replication stress inducing reagents HU and 
MMC.  
HU is a cytostatic antimetabolite that acts by inhibiting ribonucleotide 
reductase (RNR) (Koc, Wheeler et al. 2004).  At low doses HU has been shown to be 
highly cytotoxic for ATR pathway deficient cells while little effect was seen in the wild   
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Figure 3.8. Significant increased apoptosis in Hus1 mutant embryos following 
hydroxyurea treatment.  Representative sections of  Feulgen-Schiff  staining of  
Hus1neo/∆1 embryos at E8.5.  (A) Higher magnification view of  neural tube showing 
representative apoptotic (red arrow head) and mitotic (black arrow head) figures.  (B) 
Bar graph indicating the percent of  apoptotic and mitotic cells (± standard deviation) 
as determined from Fuelgen-Shiff  stained sections of  embryos of  the indicated 
genotypes. Student’s t-test identified a significant increase in apoptosis (p<0.05) in 
Hus1neo/∆1 (n=3) when compared to Hus1 controls
 
(n=9). Control genotypes include 
Hus1+/+, Hus1+/neo, and Hus1+/Δ1. 
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type control cells (Weiss, Matsuoka et al. 2002).  The toxicity associated with in vivo 
administration of HU by i.p. delivery to wild type pregnant mice showed that 
administration of a 1g/kg body weight dose at E8.5 results in embryo lethality if 
pregnancy was taken to term while 400mg/kg and 800mg/kg body weight had no 
effect on embryo survival but determined increased cell death in the central nervous 
system (CNS).  The increased apoptosis in the CNS was detectable as early as 3 hours 
post treatment.  It showed the highest levels after 12 hours followed by recovery at 48 
hours (Woo, Katayama et al. 2003; Woo, Katayama et al. 2004).  To determine the HU 
toxicity associated with Hus1 loss females from Hus1+/neo x Hus1+/ex crosses were 
injected IP with 400mg/kg body weigh HU at the E8 stage and the cell proliferation 
and apoptosis the embryos of the representative phenotypes was assessed 12 hours 
later using the Feulgen-Schiff staining technique as described in Material and Methods 
(Figure 3.8A).  No difference in the percent of mitotic or pyknotic cells was seen in 
untreated Hus1+ and Hus1neo/Δ1n genotypes.  As previously reported, HU treatment 
caused a significant decrease in the percentage of mitotic figures concomitant with an 
increase in the percentage of pyknotic nuclei, indicative of apoptosis, in the Hus1+ 
group when compared to the untreated groups.  More importantly, quantification of 
the cell proliferation and apoptosis upon treatment revealed that the Hus1neo/Δ1n E8.5 
embryos showed a significant increase in cell death but no change in proliferation 
when compared to the littermate wild-type controls (Figure 3.8 B). These data 
highlight the requirement for Hus1 in the response to HU in vivo.   
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Figure 3.9. Hus1 hypomorphic mice show hyper sensitivity to mitomycin C. 
Kaplan-Meyer survival analysis shows that Hus1neo/Δ1 mice are hypersensitive to MMC 
at both 8mg/kg (A) and 4mg/kg (B) MMC doses when compared to the Hus1+ 
littermate controls.  (C) Kaplan-Meyer survival analysis shows that Hus1neo/neoAtm-/- 
mice are hypersensitive to 4mg/kg MMC.  The cohort treated included 
Hus1+/neoAtm+/+ (n=6); Hus1neo/neoAtm+/+ (n=11), Hus1+/neoAtm-/- (n=4) and 
Hus1neo/neoAtm-/- (n=7) mice.  Mice of the indicated genotypes were treated with 
8mg/kg or 4mg/kg MMC respectively via intraperotoneal delivery. Animals were 
monitored for survival and a chi-square statistical analysis was performed. Control 
Hus1+ genotypes include Hus1+/+, Hus1+/neo, and Hus1+/Δ1. 
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Table 3.2 Major pathologic findings in Hus1neo/Δ1 mice and Hus1+ littermate controls 
after MMC treatmenta. 
Dose Genotype Major pathologic findings 
4 mg/kg 
Hus1+ 
Severe necrotizing gastritis with hyperplasia, mild colitis 
with necrosis and hyperplasia, mild tubular ectasia in the 
kidney 
Hus1neo/Δ1 Decreased white pulp in spleen, severe necrotizing 
gastritis with hyperplasia, mild colitis with necrosis and 
hyperplasia, mild tubular ectasia in the kidney 
 
aSamples were fixed in 10% formalin and processed for histology.  Hematoxilin and 
eosin stained slides were used for assessment. 
  
 
142 
 
 
 
 
Figure 3.10. Tissue morphology in mice with partial Hus1 impairment 
following 4mg/kg mitomycin C.  Tissue morphology was evaluated using 
Hematoxylin and Eosin staining (HE).  The small intestine crypts are grossly normal 
8hrs post MMC. At 96 hours post treatment both genotypic groups show enlarged 
crypts.  Additionally, at 96 hours post treatment the small intestine from the Hus1neo/Δ1 
mice showed more severe pathologies: the Hus1neo/Δ1 mice had completely disrupted 
crypts (black arrowhead) and the average crypt was larger when compared to that of 
the Hus1+ group.  Size bar corresponds to 50 microns.  Control Hus1+ genotypes 
include Hus1+/+, Hus1+/neo, and Hus1+/Δ1.  
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To extend this analysis to adult mice, MMC, a DNA cross-linking reagent was 
used. MMC toxicity in wild type mice has been tested previously.  Mice treated with 8 
mg/kg body weight MMC, representing the median lethal dose (LD50) in 14 days 
survival studies, suffer from hematopoietic, intestinal and renal toxicity (Crooke and 
Bradner 1976; Legha 1985). Mice of the Hus1+ and Hus1neo/Δ1n representative 
genotypes were treated i.p. with 8mg/kg or 4mg/kg body weigh MMC and their 
health status was monitored for 30 days.  Following treatment, independent of the 
dose used, Hus1neo/Δ1n mice showed significant hypersensitivity to MMC compared to 
the littermates controls (Figure 3.9A, B).  This shows that Hus1 is critical for the 
response to MMC in vivo.  
Because our previous research (Chapter 2) proposed that the Hus1/Atm 
interaction would be critical for the response to replication stress, and to further 
investigate the overlap between ATM and HUS1 in the response to MMC we used 
Hus1/Atm double mutant mice.  Hus1+/neo wild type-like controls and Hus1neo/neo single 
mutant mice showed no sensitivity to 4mg/kg body weight MMC.  In contrast, and as 
previously reported (Kirshner, Rathavs et al. 2009), Atm-/- single mutant mice showed 
mild MMC sensitivity demonstrated by significant loss in body weight when compared 
with wild type mice (data not shown).  Nevertheless, the Atm-/- single mutant mice 
recovered and survived treatment.  In contrast, Hus1neo/neoAtm-/- double mutant mice 
were significantly more sensitive to MMC when compared to either Hus1 or Atm 
single mutant mice, and 100% of Hus1/Atm double mutant mice died (Figure 3.9 D).  
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Thus, backed up by ATM, Hus1neo/Δ1n mice have sufficient Hus1 to deal with normal, 
physiological levels of replication stress, but when challenged with external 
genotoxins, such as HU or MMC, they become incapable to respond and show severe 
phenotypes.  Moreover, we show that Hus1 and Atm act in concert in response to 
MMC treatment, highlighting the cooperation between the ATM and ATR pathways 
in the response to replication stress in vivo. 
 
3.4.4 Similar mitomycin C induced responses in the small intestine of the 
Hus1 mutant mice. 
Because at 96 hours post treatment histopathological examination of mice 
treated with 4 mg/kg body weigh MMC revealed a Hus1 specific gastro-intestinal 
pathology (Table 3.2, Figure 3.10), characterized by increased crypt size in some crypts 
and complete depletion of others, the fate of the cells in the small intestinal crypts of 
Hus1+ and Hus1neo/Δ1n mice was assessed 8 hours and 96 hours post treatment.  
Proliferation was quantified as percentage BrdU incorporation and apoptosis through 
TUNEL staining.  8 hours post MMC treatment, there was a significant increase in 
apoptosis in both Hus1+ and Hus1neo/Δ1n mice, while at 96 hours post-treatment the 
apoptosis levels returned  to untreated levels.  No difference between the two 
genotypes was noted (Figure 3.11 A-B).  Proliferation assessment showed a different 
proliferation pattern when the two genotypes were followed at the two time points 
after MMC.  In the Hus1+ group we could detect a decrease in the proliferation of the   
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Figure 3.11. Analysis of  cell proliferation and apoptosis in the small intestine 
from Hus1neo/Δ1 as compared to Hus1+ mice following 4mg/kg mitomycin C.  
Immunohistochemical staining of  TUNEL positive cells and BrdU positive cells in 
paraffin embedded small intestine sections.  (A) Representative images depicting 
TUNEL positive cells, indicative of  apoptosis, in the small intestinal crypts from 
Hus1neo/Δ1 mice as compared to littermate controls after no treatment or the indicated 
time points after 4mg/kg MMC.  (B) Quantification of  TUNEL positive cells in the 
small intestinal crypts at 0, 8, and 96hrs post 15Gy.  8 hours post MMC treatment 
both genotypic groups showed significant increased levels of  apoptosis when 
compared to the untreated group (p<0.01; Student’s t test); no significant difference 
between the Hus1neo/Δ1 mice and littermate controls was noted.  At 96 hours although 
the crypts show severe morphology changes the apoptosis returned to untreated 
levels.  (C) Representative images depicting BrdU positive cells, indicative of  
proliferation, in the small intestinal crypts from Hus1neo/Δ1 mice as compared to 
littermate controls after no treatment or the indicated time points after 4mg/kg MMC.  
(D) Quantification of  BrdU positive cells in the small intestinal crypts at 0, 8, and 96 
hours post 15Gy.  Significant decreased levels of  proliferation were observed in the 
Hus1neo/Δ1 mice as compared to littermate controls in the untreated group (p=0.03; 
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Student’s t test).  8 hours post MMC treatment proliferation was significantly 
increased in the Hus1neo/Δ1 group (p<0.05; Student’s t test) while in the Hus1+ group 
proliferation was decreased (p=0.1; Student’s t test).  At 96 hours proliferation 
returned at similar untreated levels.  Size bar corresponds to 50 microns.  Control 
Hus1+ genotypes include Hus1+/+, Hus1+/neo, and Hus1+/Δ1.  n≥3 mice for each 
genotype and time point were used for quantitation.  Quantitation was done in intact 
intestinal crypts and n≥5 intestinal crypts per mouse were counted.  Error bars 
represent standard deviation. 
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cells of the small intestinal crypt 8 hours post MMC and a recovery to untreated levels 
at 96 hours.  In contrast, quantification of the BrdU positive cells in the Hus1neo/Δ1n 
crypts revealed that at 8 hours post treatment there was an increase in proliferation 
followed by recovery at 96 hours (Figure 3.11 B-C).  The MMC analysis of the cell 
proliferation and apoptosis in the small intestine at 8 and 96 hours post-treatment 
show that while Hus1 deficient mice present a mild proliferation phenotype cannot 
explain the associated lethality.  
Together these results show that Hus1 is critical for the response to the 
replication stress inducing reagent MMC, and that when the ATR pathway is impaired 
the ATM pathway compensates for its loss. 
 
3.5 Discussion  
The ATR pathway is critical for the response to replication stress inducing 
agents by initiating a signal transduction pathway that activates the DDR.  ATR 
pathway defective cells and organisms cannot cope with the replication induced stress 
and show lethal phenotypes.  Here we used the Hus1 mouse model as a unique genetic 
tool for the understanding of the importance of the ATR pathway in response to 
genotoxin treatment in vivo.  We show for the first time that the mice showing reduced 
Hus1 levels can respond as well as wild type mice to the DSB inducing reagent IR but 
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are hypersensitive to the replication stress reagents HU and MMC.  The data 
presented here show that in vivo there is a clear parallelism between the ATR and ATM 
pathways. 
Ionizing radiations are both a potent environmental threat for animal and 
human health as well as a key tool in the battle against cancer.  The canonical view 
that the ATM and ATR pathways act in parallel with ATM being the main responder 
to IR induced DSBs was challenged in the past decade by biochemical and cell culture 
data that showed that ATR pathway deficiency results in similar sensitivities to IR, 
proposing that ATM and ATR act as overlapping pathways.  This research proposed 
that although ATM is critical for DSB signaling the repair of such lesions require an 
intermediary step that is ATR dependent.  Our data show that mice defective for the 
ATR pathway show similar sensitivities to different IR doses as their wild type 
controls, suggesting that in vivo the two pathways act in parallel.  This idea is supported 
by our previous observation that Hus1/Atm double mutant mice are no more sensitive 
to IR stress than Atm-/- single mutants alone. Hence, Hus1 response to IR is not 
obscured by the presence of ATM.  Consistent with this observation we show that at 
the level of the small intestine and skin we can clearly detect an IR dependent 
response but no genotype specificity as both Hus1neo/Δ1n and wild type control mice 
show similar rates of cell death.  The proliferation differences present in the Hus1neo/Δ1n 
mice are independent of IR treatment highlighting the critical role for the ATR 
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pathway in highly replicating tissues.  Indeed Hus1neo/Δ1n mice are hypersensitive to the 
replication stress inducing reagents HU and MMC.  One important distinction to be 
made is that the Hus1 deficient mice are hypomorphic, thus the partial function 
present might be enough to sustain the ATR role upon IR stress.  Another option is 
that the Hus1 level is enough for ATR activation but not enough for Hus1-dependent 
repair.  Hus1 has been shown to be independently involved in base excision repair and 
translesion synthesis, both of which can be activated by replication stress (Toueille, 
El-Andaloussi et al. 2004).  In fact a similar hypothesis was proposed based on our 
previous research on the genetic interaction between Hus1 and Atm (Chapter 1).  We 
have shown that while Hus1/Atm deficient mouse embryonic fibroblast can respond 
to genotoxin insults as well as Atm single mutants, Hus1/Atm double mutant mice 
show increased GIN levels and present with severe phenotypes.  We propose that all 
of these phenotypes are a consequence of the inability of Hus1/Atm mice to deal with 
replication stress.   
To test the above we treated the Hus1 mice with the replication stress inducing 
reagents HU and MMC.  As expected the Hus1neo/Δ1 mice showed a marked sensitivity 
to these genotoxins.  The hypersensitivity of the Hus1neo/Δ1n mice is highlighted by the 
low dose required to determine lethality; at half the LD50 for wild type mice 90% of 
the Hus1neo/Δ1n mice die within 10 days of exposure.  Although the pathological 
findings showed differential pathologies when the two Hus1 genotypic groups were 
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compared (Hus1+ vs. Hus1neo/Δ1) in the gastrointestinal track, hematopoietic system and 
kidney, surprisingly no difference between the two genotypes was observed when cell 
proliferation and apoptosis was quantified at 8 hours and 96 hours in the small 
intestine.  This might be due to the time points after treatment used for sampling.  
While IR acts immediately and at the level of the entire organism, administration of 
MMC might require additional time to detect a cellular response.  
Because the kinetics of the response to MMC is different from that to IR more 
sampling time points might be necessary.  At 96 hours the intestinal crypts are so 
affected that another quantification modality might be necessary; while the 
proliferation and apoptosis levels at the level of the detectable crypts is not 
significantly different we cannot exclude that overall there are less intact crypts in the 
Hus1neo/Δ1n mice.  This argues again for an intermediary sampling point between 8 
hours and 96 hours, where this difference might be individualized.  Another plausible 
hypothesis is that the mice don’t die because of a gastrointestinal syndrome but rather 
because of another organ system is failing.  Other than gastrointestinal deficiency, in 
wild type mice MMC has been shown to determine hematopoietic syndrome and 
kidney failure.  The analysis of these systems at 8 hours and 96 hours showed that 
while we see a mild hematopoietic phenotype in the spleen and bone marrow the 
kidney is not affected.  To further understand the effect of MMC on the 
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hematopoietic system analysis complete blood counts will be performed before 
treatment and at different time points after treatment.   
The survival data indicate that the Hus1 dependent molecular mechanisms are 
involved in the response to the replication stress genotoxin MMC.  Like Hus1neo/Δ1n 
mice, the Hus1/Atm double mutants are also hypersensitive to MMC, but not IR.  
This shows that after MMC treatment Hus1neo/Δ1n and Hus1neo1eon deficient mice cannot 
repair the induced lesions that collapse into DSBs and require the ATM pathway for 
survival, thus explaining the differential sensitivity to MMC between Hus1 and Atm 
single mutants and Hus1/Atm double mutants.  Thus, in response to replication stress 
there is a clear cooperation between the two pathways to allow for survival.  We 
cannot exclude though a direct role of Hus1 in signaling to the Fanconi anemia 
complementation group genes that are critical for the response to cross-linking 
reagents like MMC (Knipscheer, Raschle et al. 2009).  Recent evidence showing that 
combined Atm/Fanconi anemia deficiency results in synthetic lethality support this 
hypothesis (Perry and Tainer 2011). 
The data presented here have an important impact on our understanding of the 
effects of the ATR pathway deficiency both in physiologic conditions as well as after 
genotoxin treatment.  Inhibitors for the ATR pathway are currently tested in clinical 
trials for cancer therapy, and our data supports the use for such inhibitors 
concomitant with replication stress inducing reagents such as HU and MMC.  We 
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show that the interaction between the two is very strong and such approaches are 
expected to give substantial results in specifically killing cancer cells if ATR pathway 
inhibition can be fine-tuned.  We also show that such approaches might be even more 
efficient for tumors that are deficient for the ATM pathway, which may represent as 
many as 30% of all cancers. 
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CHAPTER 4 
SUMMARY, MODELS, AND FUTURE DIRECTIONS 
HUS1 plays a critical role in ATR pathway activation as part the 911 complex, and 
germline deletion of Hus1 results in early embryonic lethality (Weiss, Enoch et al. 
2000).  This lethality phenotype was overcome by engineering Hus1 hypomorphic 
alleles where Hus1 was disabled to different degrees.  The Hus1 impaired mice show 
no overt phenotypes, are born at expected mendelian frequencies, have no increased 
predisposition to forming tumors but have increased genomic instability (Levitt, Zhu 
et al. 2007).  These observations suggest that Hus1 deficient mice rely on other 
pathways to promote organism survival and that although the low levels of Hus1 
present are enough for the response to normal replication stress they might not be 
enough when this pathway is challenged. 
Although much was known about the relationship between the ATM and ATR 
pathways in cell culture, less was known about the in vivo relationship between these 
pathways due to the limited mammalian models available for Atr deficiency.  
Moreover, since ATR pathway inhibition shows such promising results for cancer 
treatment efficacy (Brooks, Oakes et al. 2012; Tang, Dai et al. 2012), it was imperative 
to learn more about the effect of ATR deficiency in normal tissues.  Here we took 
advantage of the unique Hus1 mouse model to answer these questions. 
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4.1 Disease severity in a mouse model of Ataxia Telangiectasia is modulated 
by the DNA damage checkpoint gene HUS1 
We show that simultaneous Atm and Hus1 defects caused phenotypes that were 
not merely additive but strongly synergistic.  The lowest level of Hus1 in the allelic 
series, which on its own is fully compatible with normal development, resulted in 
high levels of apoptosis and mid-gestational lethality in the absence of Atm.  
Increased H2AX phosphorylation and p53 accumulation also were observed, 
revealing that the checkpoint apparatus is remarkably robust, permitting DNA 
damage signaling even when the two primary checkpoint pathways are dysfunctional 
(Figure 4.1).  A less severe Hus1 defect resulted in partial embryonic lethality in the 
context of Atm deficiency.  Surviving Atm/Hus1 double mutant mice showed severe 
dwarfism, craniofacial abnormalities, and digit abnormalities, phenotypes that could 
not have been predicted based on knowledge of the individual single mutants. 
Unlike what has been observed in other DNA repair mutants, the striking 
dwarfism in Atm/Hus1 double mutant mice was independent of the GHR/IGF1 
axis.  The craniofacial defects, which resemble those seen in human patients with 
genomic instability syndromes, stemmed from defects in a specific subset of cells in 
the skull and illustrate how checkpoint failure differentially impacts particular lineages 
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Figure 4.1. Hypothetical model showing synthetic lethal interactions following 
Atm inactivation and partial Hus1 impairment.  Previous studies have indicated 
that Hus1 impairment leads to the accumulation of DSB due to defects in checkpoint 
signaling and/or repair (Weiss, Enoch et al. 2000; Levitt, Zhu et al. 2007; Zhu and 
Weiss 2007).  We hypothesize that DNA damage that arises when Hus1 expression is 
sub-optimal creates a greater requirement for ATM-mediated genome protection and 
leads to synthetic lethality in Atm/Hus1 double mutant mice.  The fact that activation 
of canonical checkpoint signaling factors such as CHK2, CHK1, and p53 appeared 
similar in Atm single and Atm/Hus1 double mutants suggests that ATR may remain 
active in the context of modest HUS1 impairment or that other DNA damage-
responsive kinases, such as DNA-PK, can mediate the signaling as illustrated. See text 
for additional details. 
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The highly specific consequences of defective genome maintenance were further 
apparent from our analysis of the double mutant limbs, where one particular bone 
(the mesophalanx of digit V) was affected.  The same abnormality is observed in 
certain human genomic instability syndromes as well as following fetal teratogen 
exposure, suggesting that it may be a broader indicator of developmental genomic 
instability.  Overall, the constellation of phenotypes in the Atm/Hus1 double mutant 
mice is similar to that observed in a severe variant form of A-T, A-TFresno, raising the 
possibility that HUS1 or other ATR pathway components could be modifiers of A-T 
disease severity in humans. 
Moreover, the developmental phenotypes in Atm/Hus1 double mutant mice were 
associated with synergistic increases in genomic instability, but tumor-free survival 
was unaffected.  That tumor development was not altered despite significantly 
increased genomic instability further illustrates the complex tissue-specific 
consequences of checkpoint failure, findings with important implications for cancer 
therapy strategies based on checkpoint inhibition.  Of particular note with respect to 
the underlying molecular mechanisms is our observation that despite the combined 
defects in two checkpoint genes, checkpoint signaling was not further impaired 
beyond what is observed in the respective single mutants.  In fact, the basal level of 
checkpoint signaling was actually increased in double mutant cells, leading us to 
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propose a model in which DNA repair defects associated with Hus1 impairment 
drive the synthetic phenotypes.  
4.2 ATM pathway mediates the primary response to IR, while HUS1 and the 
ATR pathway are the in vivo responders to replication stress 
The lack of a mouse model for ATR pathway deficiency impeded the analysis of 
the subsequent effects on the response of normal tissues to replication stress as well 
as their response following chemotherapeutic treatment.   
While the role for the ATM pathway in response to genotoxin treatment was 
extensively described in vivo little was known about the ATR role in response to 
different clastogens.  For the first time we show that in vivo Hus1 is not obligatory for 
the response to IR since upon different treatment doses no significant differences are 
seen between the Hus1neo/∆1n group and the control Hus1+ group.  Moreover, analysis 
of different tissues at specific time points post-IR showed minimal Hus1 dependency.  
Together with data from the Hus1/Atm double mutant mice showing that Hus1 does 
not impact the IR sensitivity of Atm-/- mice, we conclude that the ATM pathway is 
the main responder to DSBs inducing genotoxins in vivo (Figure 4.2). 
On the other hand analysis of the in vivo sensitivity to the replication stress 
reagents MMC and HU showed that at very low doses, Hus1neo/∆1n impaired mice 
readily die underlining a severe requirement for HUS1 and the ATR pathway.  The  
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Figure 4.2.  Hypothetical model showing the interaction between the ATM 
and ATR pathways in response to genotoxic stress caused by IR or MMC.  
While Atm null mice are hypersensitive to IR independent of the Hus1 status, 
suboptimal Hus1 expression creates a greater requirement for ATM-mediated genome 
protection to DSBs and leads to synthetic lethality in Atm/Hus1 double mutant mice 
upon increased replication stress as caused by MMC.  We propose that because of 
synthetic lethal interaction impairment of the ATR pathway through specific 
inhibitors can be used to sensitize tumor cells to specific chemotherapies. 
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survival data presented, gives clear hints on the molecular mechanism underlying 
these sensitivities.  HUS1 is necessary for the response to MMC induced lesions and 
when HUS1 levels are low in the Hus1 impaired mice these lesions, most likely stalled 
forks, collapse and are transformed into DSBs that are repaired by the ATM 
pathway.  This is highlighted by the fact that while Hus1neo/neo  or Atm-/- single mutant 
mice show no sensitivity to MMC, Hus1neo/neoAtm-/- mice are hypersensitive to the 
same dose although they show no specific hypersensitivity to IR when compared to 
Atm-/- single mutants alone (Figure 4.2).  We need to further understand though what 
are the specific molecular steps that require HUS1 for the repair of MMC induced 
lesions.  We hypothesize that HUS1 might be important for the ATR mediated 
signaling to FA complementation group or could play an important repair role, 
independent of ATR.  
Corroborated with current data from our laboratory and from others that show 
that components of the ATR pathway, including RAD9, RAD1, HUS1, and CHK1, 
are important for tumor progression (Bartek, Mistrik et al. 2012; Brooks, Oakes et al. 
2012; Ma, Cai et al. 2012; Origanti, Cai et al. 2012; Tang, Dai et al. 2012; Stephanie A. 
Yazinsky in preparation) we think that ATR pathway inhibitors could be successfully 
associated with chemotherapy to specifically kill cancer cells.  Moreover, based on 
the data presented in this thesis, critical for the success of such therapies will be an  
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Figure 4.3. Distinct roles of the DDR pathways during multistep 
tumorigenesis.  In normal circumstances the transformation of normal cells 
(depicted in black) to transformed cells is kept in check by the ATM pathway.  If the 
ATM pathway gets mutated (depicted in red are cells defective for ATM pathway that 
would eventually initiate a tumor), protection is lost and tumor progression takes 
place.  ATM deficiency comes with a great toll for these cancers that become 
defective for the response to DSBs formation and thus sensitive to 
chemotherapeutics.  With time, the cancer cells become resistant to these treatments 
because they adapt to the increased GIN by upregulation of the activity of the ATR 
pathway.  The ATR pathway is proposed to play an important role in this adaptation 
and future tumor survival by allowing them to deal with replication and genotoxin 
induced stress.  Based on our data, in these instances, a cocktail of MMC/ATRi would 
specifically kill the cancer cells with very little effect on normal surrounding cells since 
these cells are intact for the ATM pathway. 
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initial understanding of the ATM pathway status of these tumors as well as their 
replication potential.  We predict that ATM pathway deficient tumors would be highly 
sensitive to low doses of MMC combined with ATR pathway inhibitors while normal 
surrounding tissues that are ATM proficient will suffer very mild toxicity (Figure 4.3).  
 
4.3 Future Directions 
While the data presented here ilustrate the strong relationship between the main 
DDR pathways lead by ATM and ATR for both for development and cancer 
protection many surprising observations remain unexplained.  
HUS1 and ATM cooperate for normal development but the requirement for 
this interaction is limited to specific cell populations, since this combined deficiency 
results in very specific phenotypes.  Since we see increased GIN during development 
and in the hematopoietic system in the adult but not in the liver that is a replication 
quiet organ we think that the replication status of a specific tissue is critical for this 
interaction.  More experiments are needed to be done to clearly demonstrate this 
hypothesis.  Moreover, we think that different cell types deal differently with lack of 
these factors.  This was previously observed in the Hus1 conditional knock-out, where 
Hus1 deletion was better supported in the lung and mammary gland, highlighting   
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Table 4.1.  Association between genomic instability syndromes and 
developmental defects.   
 Genomic instability (GIN); growth retardation (GR); craniofacial defects (CD) and 
brachymesophalangy V (BMP-V); the data was parsed using OMIM database.   
Syndrome OMIM Gene GIN GR CD BMF-V  
Ataxia Telangiectasia 
(A-T) 
208900 ATM + + - - 
Seckel Syndrome 
(SCKL) 
210600 ATR + + + + 
Nijmegen Breakage 
Syndrome (NBS) 
251260 NBS1 + + + + 
Ataxia Telangiectasia 
like (ATLD) 
 MRE11 + + - - 
Williams-Beuren 
Syndrome 
194050 
del7q11.23 
(RFC2) 
+   + 
Rothmund Thomson 
Syndrome 
268400 REQ4 +   + 
Bloom Syndrome 604610 BLM +  + + 
Warsaw Breakage 
Syndrome 
613398 DDX11 + + + + 
Fanconi anemia 605724 >11 genes + +  + + 
Trichothiodystrophy 278730 XPD + - - + 
Lig4 Syndrome 606593 Lig4 + + + + 
Nijmegen breakage 
syndrome-like 
disorder 
604040 Rad50 + + + + 
Lig1 Syndrome 126391 Lig1 + + -  
Werner syndrome 277700 WRN + + - + 
Omenn Syndrome 603554 Artemis + + - - 
Severe Combined 
Immune Deficiency 
Syndrome 
600899 DNA-PK + + - - 
NHEJ1 Syndrome  611290 NHEJ1 + + + + 
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varying requirements in different tissues (Levitt, Liu et al. 2005).  We think the same 
happens in the Hus1/Atm double mutant mice where the craniofacial phenotype as 
well as the lack of a difference in tumor predisposition could be attributed to different 
tissue sensitivities.  This could be done both at the level of the embryo as well as in 
adults, with and without genotoxin treatment.  Transcript analysis by Q-PCR for 
members of the two pathways (p21, PUMA, Bax etc.) as well as 
immunohistochemistry staining for γ-H2AX and p53 could be executed in spleen, 
kidney, small intestine, thymus, brain, liver and testes(ovaries) of the Hus1/Atm 
double mutant mice and compared to the representative littermate controls. 
 The dwarfism present in our mice remains a very interesting phenotype to be 
dissected.  One question that remains to be answered is if the hormonal growth 
pathways are intact in our mice.  While Igf1 and GhR are not deregulated we cannot 
reject the implication of the Igf1 binding proteins (IGF1BP) or other Igf family 
members (Igf2; Igf1R) in the promotion of this phenotype.  For all these factors 
transcript analysis by Q-PCR from E13.5 and neonatal livers could be performed.  
Additionally, to completely rule out the implication of the IGF1BP’s ELISA assays 
could be performed from the serum of our mice to establish if the circulating levels of 
these proteins is changed.  Preliminary Igf1R transcript analysis revealed no change in 
the level of this transcript in E10.5 embryos (Figure 4.4.A).  Moreover I think that we 
will see no difference in the levels of the IGF1-BP because of the direct correlation 
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between IGF1 levels and IGF1-BP3 (that is 80% of the IGF-BP`s that binds IGF1 
the rest is shared by the other 6 IGF1-BP) (Robinson 2010).  Although initially we 
have postulated that this phenotype could arise due to increase cell death at the level 
of the bones growth plates, as reported in other dwarf models (Li, Chen et al. 1999), 
preliminary analysis showed that the growth plates of the Hus1/Atm double mutant 
mice have similar morphologies in all the mice, excluding this hypothesis (Figure 
4.4B).  We thus favor the idea that the dwarfism is due to a cell autonomous defect: 
the increased GIN during development results in marked cell death causing the 
depletion of both somatic and stem cells thus creating a cellular shortage translated 
into a small body size. 
 The skeletal defects featured by the Atm/Hus1 mice are also very striking.  We 
think that the craniofacial defects could be due to an increase cell death in particular 
cell niches, like the neural crest progenitor cells.  Like in a mouse model for Treacher-
Collins syndrome (Jones, Lynn et al. 2008), I would expect this to be due to increased 
cell death in this compartment via a p53 dependent mechanism.  Furthermore the 
embryo analysis performed in the Hus1/Atm double mutant showed increased p53 
levels that correlated with increased apoptosis.  To test this, mice of the representative 
genotypes could be treated during embryonic development (starting E6.5 daily) with a 
potent p53 inhibitor, pifithrin-alpha (Alexis Biochemicals) at 2.2 mg per kg (body 
weight) in PBS by intraperitoneal injection.  Inhibition of p53 could lead to apoptosis 
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inhibition triggering the abolition of the craniofacial phenotype (McKeown and 
Bronner-Fraser 2008).  Moreover p53 inhibition might save the dwarfism phenotype 
like in the case of the Treacher-Collins mouse model (favoring the cell autonomous 
hypothesis).  The caveat of such an experiment would be related to the toxicity 
associated with pifithrin-alpha daily injection or because Hus1 has been implicated in 
p53-independent apoptosis (Yazinski, Westcott et al. 2009).  
The brachymesophalangy V phenotype is a unique and very specific phenotype.  
Recently, it has been shown that deletion of mir-17-92 cluster in mice causes an array 
of developmental defects including brachymesophalangy V (Ventura, Young et al. 
2008; de Pontual, Yao et al. 2011). Additionally the mir-17-92 cluster has been shown 
to be repressed by p53, fitting well with our model where p53 is activated (Yan, Xue 
et al. 2009).  The mir-17-92 family of miRNA is composed of 3 related polycistronic 
miRNA genes that collectively encode for a total of 15 miRNAs (Concepcion, Bonetti 
et al. 2012).    To test if the brachymesophalangy V arose due to mir17-92 depletion 
we have performed Taq-Man Q-PCR analysis and analyzed the levels of two of the 
mature mir17-92 members (mir17 and mir19b) –(Figure 4.5 A) as well as the levels of 
expression of the two pri-miRNA’s (Figure 4.5B).  Our preliminary analysis didn’t 
reveal any difference in the transcript levels of the mir17-92 family members.  
Although at this point we cannot completely exclude the deregulation of this cluster 
we think that in the Feingold syndrome model the mir17-92 depletion is a secondary   
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Figure 4.4. Analysis of the dwarfism phenotype in Hus1/Atm double mutant 
and control mice. (A) Bar graph shows the fold expression level of Igf1R in E10.5 
from embryos (n=3) of the indicated genotypes relative to Hus1+/neoAtm+/+.  Total 
RNA was extracted using RNA STAT-60 reagent (Tel-Test, Friendswood, TX) and 
SYBR Green Q-PCR using the forward (TGCTGTCTATGTCAAGGCTG) and 
reverse (AGAGGAAGAGTTTGATGCTGAG) Igf1R primers.  No significant 
differences were detected.  (B) Tibias dissected from 6-week old littermate male mice 
of the indicated genotypes were isolated, decalcified and processed for 
histopathological staining.  Sarfanin O staining differentially detects the cartilage, 
mucin, and mast cell granules on formalin-fixed, paraffin-embedded tibia tissue 
sections.  Representative 40X images of the growth plates of the representative 
genotypic groups show no difference in the morphology of the growth plates.    
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effect to activated p53 due to possible increased GIN.  Many human genomic 
instability syndromes present with brachymesophalangy V and teratogen exposure 
during pregnancy leads to similar phenotypes (Mancinelli, Binetti et al. 2007).  To test 
this hypothesis wild-type mice could be treated with HU during embryonic 
development and the digit phenotypes of the offspring could be assessed.  In parallel 
Q-PCR analysis for the other mature members of the mir17-92 pathway could be 
performed.  If the GIN hypothesis stands true, then we would expect that the mir17-
92 mice to have increased GIN, while other DDR mutant mice should present 
brachymesophalangy V, and indeed preliminary data shows that the ATRS/S mice 
show similar defects.  These observations would have an important impact on our 
understanding of the effects of GIN during development and would also point to a 
specific skeletal defect that could be used for diagnosis of genomic instability 
syndromes during early pregnancy.  
 The analysis of the DDR response in the Hus1/Atm primary MEFs, revealed 
no signaling defect.  We think that this might be due to the redundancy with another 
PIKK, DNA-PK.  To test this we could use DNA-PK specific inhibitors and test if 
this inhibition could abolish signaling in the double mutant MEFs.  Because 
preliminary analysis shows that the DNA-PK involvement is minimal we favor the 
hypothesis that the level of Hus1 present in our mice is sufficient for promoting ATR 
signaling, and the increased GIN that we see is due to a Hus1 repair defect.  To test   
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Figure 4.5. Figure 4.4. Analysis of the mir17-92 expression level in the 
Hus1/Atm double mutant and control mice. (A) Bar graph shows the fold 
expression level of primary microRNAs (pri-miRNAs) of the mir17-92’s using total 
RNA E10.5 embryo samples (n=3) from embryos of the indicated genotypes relative 
to Hus1+/neoAtm+/+.  Pri-miRNA are long noncoding RNA transcripts with at least one 
precursor microRNAs (pre-miRNAs) containing mature microRNA 17-92 cluster 
(miRNA) sequences.  No significant differences were detected.  (B) Bar graph shows 
the fold expression level of mir17 and mir-19b in total RNA E10.5 embryo samples 
(n=3) from embryos of the indicated genotypes relative to Hus1+/neoAtm+/+. No 
significant differences were detected.  
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this hypothesis we could use ATR inhibitors in MEFs and I propose that upon 
treatment signaling to the downstream kinase CHK1 could be diminished.    
 The analysis of the Hus1 requirement for genotoxin response in vivo showed a 
very clear survival difference: Hus1 is not required for IR response but is critical for 
MMC response.  The analysis of cell proliferation and apoptosis in the MMC small 
intestine samples showed though no significant difference in apoptosis at the different 
time points when the correspondent genotypes were compared.  This might be due to 
that fact that the MMC lethality is due to increased cell death in another 
compartment, like the hematopoietic system, or because we are not looking at the 
right time interval. Histopathology assessment of MMC treated samples revealed a 
splenic pathology consistent with increased anemia.  To test this hypothesis Hus1 
impaired mice and littermates controls could be treated with a 4mg/kg MMC and 
complete blood counts (CBC’s) could be performed at 0, 24, 48 and 76 hours.  This 
will allow us to see if anemia is a specific pathology in the Hus1 impaired mice.  We 
could complete the analysis with the exploration of the cell proliferation and 
apoptosis following MMC at additional time points (2hrs and 24 hours). 
 To resolve the mechanistic role for Hus1 in cross-link repair we could use both 
tissues and MEFs from Hus1 impaired mice from MMC treated and untreated groups 
and test for the effect of Hus1 deregulation on signaling to the FA complementation 
group.  We could test the activation level of FancD2, a protein positioned 
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downstream of ATR and target of its phosphorylation.  Additionally, if signaling is 
intact we could test the involvement of HUS1 directly in repair by looking at the 
accumulation of cross-link repair factors like MUS81. 
 Finally, based on our model Atm/Hus1 deficient tumor cells should be 
hypersensitive to low levels of MMC when compared to the single mutants alone.  To 
test this hypothesis we could isolate thymic tumor T cells from either Atm-/- or 
Hus1/Am double mutant mice and subject them to MMC treatment.  We expect that 
the Hus1/Atm T cells could readily die when compared to the Atm-/- single mutant 
ones, confirming our model (Figure 4.3).  If this holds true we could cross Hus1 on 
different tumor bearing backgrounds and re-test our hypothesis.  These observation 
will bring vital information on the use of ATR inhibitors for cancer therapy and 
propose HUS1 specifically for the development of small molecule inhibitors. 
 Together the data presented here outline the importance of the Hus1 gene for 
both development and the response to genotoxins and proposes a model where 
HUS1 or ATR impairment could be used in our fight against cancer.  
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